Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific
- Liang-Kung Chen1, 2Email author,
- Hidenori Arai3,
- Liang-Yu Chen1,
- Ming-Yueh Chou2, 4,
- Samsuridjal Djauzi5,
- Birong Dong6,
- Taro Kojima7,
- Ki Tae Kwon8,
- Hoe Nam Leong9,
- Edward M. F. Leung10,
- Chih-Kuang Liang2, 4, 11,
- Xiaohong Liu12,
- Dilip Mathai13,
- Jiun Yit Pan14,
- Li-Ning Peng1, 2,
- Eduardo Rommel S. Poblete15,
- Philip J. H. Poi16,
- Stewart Reid17,
- Terapong Tantawichien18 and
- Chang Won Won19
© The Author(s). 2017
Received: 5 March 2016
Accepted: 9 January 2017
Published: 15 March 2017
Herpes zoster (HZ) is a prevalent viral disease that inflicts substantial morbidity and associated healthcare and socioeconomic burdens. Current treatments are not fully effective, especially among the most vulnerable patients. Although widely recommended, vaccination against HZ is not routine; barriers in Asia-Pacific include long-standing neglect of adult immunisation and sparse local data. To address knowledge gaps, raise awareness, and disseminate best practice, we reviewed recent data and guidelines on HZ from the Asia-Pacific region.
We searched PubMed, Scopus, and World Health Organization databases for articles about HZ published from 1994 to 2014 by authors from Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. We selected articles about epidemiology, burden, complications, comorbidities, management, prevention, and recommendations/guidelines. Internet searches retrieved additional HZ immunisation guidelines.
From 4007 retrieved articles, we screened-out 1501 duplicates and excluded 1264 extraneous articles, leaving 1242 unique articles. We found guidelines on adult immunisation from Australia, India, Indonesia, Malaysia, New Zealand, the Philippines, South Korea, and Thailand.
HZ epidemiology in Asia-Pacific is similar to elsewhere; incidence rises with age and peaks at around 70 years – lifetime risk is approximately one-third. Average incidence of 3–10/1000 person-years is rising at around 5% per year. The principal risk factors are immunosenescence and immunosuppression. HZ almost always causes pain, and post-herpetic neuralgia is its most common complication. Half or more of hospitalised HZ patients have post-herpetic neuralgia, secondary infections, or inflammatory sequelae that are occasionally fatal. These disease burdens severely diminish patients’ quality of life and incur heavy healthcare utilisation.
Several countries have abundant data on HZ, but others, especially in South-East Asia, very few. However, Asia-Pacific countries generally lack data on HZ vaccine safety, efficacy and cost-effectiveness. Physicians treating HZ and its complications in Asia-Pacific face familiar challenges but, with a vast aged population, Asia bears a unique and growing burden of disease. Given the strong rationale for prevention, most adult immunisation guidelines include HZ vaccine, yet it remains underused. We urge all stakeholders to give higher priority to adult immunisation in general and HZ in particular.
KeywordsAsia-Pacific Complications Epidemiology Healthcare burden Herpes zoster Immunisation Management Post-herpetic neuralgia Prevention Vaccine
Herpes zoster (HZ) is a prevalent and debilitating viral disease that often causes serious complications and proves challenging to treat. Consequently, HZ results in substantial morbidity, healthcare expenditure, loss of productivity, and diminished quality of life (QoL). Older people bear the greatest burden of disease, which is increasing as populations age. Despite a strong rationale for prevention, availability of an effective vaccine, and guidelines recommending HZ immunisation, vaccination has not become routine practice. One reason was limited availability of HZ vaccine after its launch in 2006 [1, 2]. Although an ample supply was restored, a fundamental barrier in Asia is long-standing neglect of preventive adult healthcare. Since Ilina Isahak highlighted this issue in 2000 , progress been limited and adult immunisation is still not given the priority that it merits [4, 5, 6]. Moreover, existing HZ immunisation guidelines are based on evidence from Western populations, which creates a perceptual barrier to changing management practices in Asia. Conversely, more locally-relevant data may promote guideline implementation; however, many Asian countries lack such data . To address these concerns, we systematically reviewed literature on HZ from the Asia-Pacific region. Our objectives were: 1) To provide a comprehensive overview of the epidemiology, burden, and current management of HZ; 2) To disseminate best practice in HZ immunisation; and 3) To provide an up-to-date source of reference and information for stakeholders concerned with reducing the burden of HZ in Asia-Pacific. This review summarises our key findings and recommendations.
Literature search strategy
We reviewed literature on HZ published over 21 years by authors from 14 Asia-Pacific countries. We searched three databases: PubMed (United States [US] National Library of Medicine National Institutes of Health), Scopus (Elsevier), and the World Health Organization (WHO) Global Health Library Regional Indexes. PubMed and Scopus searches used the search term ‘zoster’ in title, abstract, and author keywords fields, AND the term ‘country name’ in the affiliation field. The countries/regions were: Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, and Vietnam OR Viet Nam. WHO searches used the terms ‘country name’ AND ‘zoster’. Searches were limited to articles with abstracts in English published electronically since 1 January 1994 and before 31 December 2014; alerts were set to capture eligible articles added to PubMed and Scopus after the initial search dates.
We performed separate internet searches for guidelines on HZ immunisation. These used the country names and also vernacular terms for their inhabitants, eg, Thai, Filipino, Malay, combined with the terms herpes zoster, guidelines, recommendations, adult immunisation, vaccine, vaccination.
PubMed and Scopus results were downloaded in Comma Separated Value format then saved to Microsoft Excel files. WHO Global Health Library searches were exported as text files then imported into Microsoft Excel. Results from each database were screened to remove duplicates before entering the results for each country into a Microsoft Excel workbook. Duplicates between databases were identified by using conditional formatting to highlight entries with the same title. Duplicates between countries were identified similarly, by highlighting entries with the same database identity codes.
Inclusion and inclusion criteria
We included articles about four topics: epidemiology and burden; complications and comorbidities; management and prevention; and recommendations/guidelines. We excluded articles about: subjects only younger than 18, or from another country; primary varicella zoster virus (VZV) infection or not specifying that VZV infection was reactivated; negative disease associations, cases of coincidental HZ, or diseases other than HZ; extraneous research topics, eg, basic/molecular/experimental, diagnosis, technology; or reviews without country-specific information. Miscellaneous exclusions were editorials, correspondence or errata concerning included articles; study protocols, and articles on terminology, hypotheses, non-human subjects, or knowledge, attitudes and behaviour relating to HZ and its treatment.
Literature search results
‘Grey literature’ included other key studies/data cited in retrieved articles or not stored in the searched databases, eg, national statistics or reports published locally; 16 such sources were added.
Reactivated VZV can affect any part of the body. Ocular symptoms due to involvement of the ophthalmic division of the trigeminal nerve are common ; however, the maxillary and mandibular branches may occasionally be affected, resulting in oro-cutaneous manifestations [35, 36]. Atypical presentations usually reflect underlying immunocompromise, and other unusual locations have included the eardrum , genitalia [38, 39], papilla , and finger .
Zoster sine herpete
VZV reactivation does not always manifest cutaneously. Zoster “sine herpete” causes unexplained pathologies, including neuralgia , ocular , facial , or neuromotor palsy or paralysis [45, 46], and cerebral or ocular inflammations [47, 48].
Multidermatomal, disseminated and visceral HZ
Rarely, especially in patients who are elderly or otherwise immunocompromised, HZ involves two or more distinct dermatomes [49, 50], spreads across multiple sites [51, 52], appears as a generalised rash [53, 54], or worse, affects internal organs [9, 10]. Although occasionally seen in immunocompetent individuals [55–64], such unusual presentations constitute fewer than 1% of total cases, being particularly characteristic of iatrogenic immunosuppression in transplant recipients [65, 66] or cancer patients [67–71], or human immunodeficiency virus (HIV) infection, in which bilateral [72, 73], multidermatomal , disseminated , or recurrent [73, 76, 77] HZ are often the presenting symptom [72, 78–80].
Disseminated HZ predicts higher risk of complications  and may portend abdominal HZ, which has high mortality despite antiviral therapy, especially in profoundly immunocompromised patients [9, 10, 82]. For example, haematopoietic stem cell transplant (HSCT) recipients have died of fulminant VZV hepatitis [83, 84]. Such patients may present with severe abdominal pain [82, 85–87] either sine herpete or before lesions appear [9, 10]. Besides hepatitis, viscerally disseminated HZ may also cause pancreatitis [88, 89], colitis , pneumonitis [91, 92], or pneumonia [69, 93], which causes most fatalities .
Irrespective of its outward appearance, pain is the hallmark of HZ in adulthood. Acute pain and post-herpetic neuralgia (PHN) are its most unbearable and debilitating symptoms and severely impair QoL and everyday activities [15, 18, 20, 30]. Pain is notoriously challenging to manage, especially once established, making this the most compelling reason for early intervention [9, 25, 94, 95].
Almost all adult HZ patients suffer pain, which can be excruciating and is often described as the worst ever experienced [10, 96]. Many cases are presaged by prodromal neuralgia or malaise, with abnormal sensations such as itching, paraesthesia and hyperaesthesia [10, 18]. In India, Korea, Singapore and Taiwan, around two-thirds of patients reported prodromal pain, which more than 90% rated moderate-to-severe [18, 20, 25, 31]. Among 150 Taiwanese patients, 98% had acute pain at enrolment (87% moderate-to-severe) ; similarly, 95% of Indian and Singaporean patients experienced pain during the course of disease [12, 18]. Pain is more frequent and severe in older patients and can have devastating impacts; patients feel anxious and miserable, have disturbed sleep and cannot work normally or enjoy life [10, 12, 15, 18, 20, 25, 30]. Besides age, the severity and duration of acute herpetic pain correlates with the degree of prodromal pain, the severity of skin lesions, trigeminal/ophthalmic involvement, anxiety or depression, and comorbid disease [23, 32, 33, 97–100].
Epidemiology and risk factors
Herpes zoster incidence rates in Asia-Pacific
Age range (years)
Incidence (cases/1000 person years)
Australia (MacIntyre 2003) 
Japan (Toyama 2009) 
0– ≥ 90
New Zealand (Reid 2014) 
Korea (Kim YJ 2014) 
0– ≥ 80
Korea (Kang 2008) 
Korea (Choi 2010) 
Korea (Park SY 2004) 
Thailand (Aunhachoke 2011) 
Taiwan (Wu PY 2013) 
Taiwan (Wu CY 2010) 
20– ≥ 60
Taiwan (Chao DY 2012) 
Taiwan (Jih 2009) 
1– > 80
Taiwan (Lin 2010) 
≤1– ≥ 80
Quartile range (IQR)
Trends in herpes zoster incidence, hospitalisation and healthcare costs in Asia-Pacific countries
Herpes zoster rate
Annual increase (%)
Australia (Kelly 2014) 
Australia (Nelson 2010) 
Management/1000 GP consultations
Australia (MacIntyre 2003) 
Australia (Carville 2010) 
Australia (Heywood 2014) 
Korea (Choi 2010) 
Total socioeconomic cost (US$)
Japan (Toyama 2009) 
Taiwan (Lin 2010) 
Healthcare cost (NT$)
Taiwan (Wu CY 2010) 
Taiwan (Chao DY 2012) 
Taiwan (Wu PY 2013) 
Thailand (Bureau of Epidemiology)
Reported cases/100000 population
Quartile range (IQR)
Asia-Pacific countries with national varicella immunisation programmes
Varicella vaccine schedule
Planned extent of coverage
Programme commenced (month, year)
18 months, with catch-up at 10–13 yearsa
12 months & 6 yearsb
Entire population (voluntary category)c
15 months, with catch-up at 11 yearsd
Risk factors and comorbidities
Organ, tissue or cell transplant recipients require immunosuppressive therapy with cyclosporine and/or other drugs that prevent transplant rejection. Consequently, they often develop HZ or other opportunistic infections, especially within the first year following transplantation [16, 66, 169–180]. HZ rates of up to >80% have been reported [170, 181], and transplant recipients are especially prone to disseminated and visceral HZ with potentially fatal inflammatory complications [70, 82, 181–186].
Anti-inflammatory and cytotoxic agents
Cyclophosphamide and others
Cyclophosphamide-based and other chemotherapeutic regimens substantially increase the risk of HZ in patients with lymphoma [190–192]. High rates have also been reported in leukaemia patients treated with arsenic trioxide [193–196]. Systemic lupus erythematosus (SLE) and lupus nephritis are also treated with cyclophosphamide, often combined sequentially with azathioprine and prednisolone or mycophenolate mofetil. HZ is the most common drug-related infection, with rates of up to 40% [166, 197–201].
HZ is also an adverse effect of azathioprine and mycophenolate mofetil in SLE and other therapeutic settings [202–214]. Cases of disseminated HZ have occurred in rheumatoid arthritis patients treated with leflunomide, with increased risk in those taking concomitant methotrexate and corticosteroids [215, 216]. HZ was the most common infection in leflunomide-treated lupus nephritis . The multiple sclerosis drug cladribine is associated with an increased rate of HZ versus placebo .
Antibody therapies for cancer, transplant rejection and other conditions are associated with elevated rates of VZV reactivation, both alone and combined with other biologics or chemotherapies. These include alemtuzumab , rituximab [220–224], and abatacept . Tofacitinib is associated with significantly higher rates HZ in Asians than other races [226, 227]. Increased relative risk of HZ has also been reported with ustekinumab, adalimumab and infliximab [165, 228–230].
Bortezomib Bortezomib directly impairs CMI and is an independent risk factor for HZ , with incidence of up to 40% in some Asia-Pacific studies [231–250]. HZ prophylaxis is advisable before commencing such therapy .
Other iatrogenic risk factors
Accidental or iatrogenic trauma can trigger HZ [252–258]. This is particularly associated with ocular, facial or dental surgeries [259–268], and heightened vigilance is warranted following such procedures, particularly in elderly or immunocompromised patients. Ironically, neurosurgical treatment of PHN occasionally causes HZ [269–271].
General anaesthesia may compromise immune function, and mothers anaesthetised for caesarean delivery have a small increased risk of HZ during the following year .
Drug-induced hypersensitivity syndrome
Drug-induced hypersensitivity is a severe reaction to certain drugs that involves the reactivation of herpes viruses, including VZV. Systemic corticosteroids may contribute to this risk, and like immune restoration syndrome, withdrawal of corticosteroid may trigger HZ .
HIV/Acquired Immunodeficiency Syndrome (AIDS) is a major healthcare problem in Asia. With prevalence of up to 30% and incidence as high as 40–50/1000 PY [276–303], HZ is so common in HIV-infected individuals that it may be a pragmatic prognostic marker [14, 27, 28, 76], especially among younger individuals [304–309]. AIDS patients may have recurrent [73, 76, 77, 80], disseminated [27, 78], or cerebral HZ infections [310, 311]. HZ incidence correlates with low CD4+ cell count [310, 312–314] and may be significantly reduced by highly-active antiretroviral therapy (HAART); however rates in the post-HAART era remain double-digit [281, 303].
Immune reconstitution syndrome Paradoxically, patients regaining immunocompetence following HAART are at higher risk of HZ than when immunodeficient, probably due to increasing CD8 cell count, a phenomenon termed immune reconstitution inflammatory syndrome [315–318].
Varicella zoster virus
Counterintuitively, Taiwanese healthcare workers frequently exposed to VZV did not gain enhanced immunological protection, and had higher incidence of HZ than the general population; however, this may be because their very stressful working environment dampened CMI, overriding any protective effect . Epidemiology data from Japan  and elsewhere suggests that varicella exposure boosts immunity to HZ [102, 151]. Nevertheless, rare localised HZ clusters suggest that VZV re-exposure might occasionally provoke recrudescent HZ; the mechanism is unknown, but may involve disruption of CMI by the humoral response to VZV reinfection . Although VZV transmission from patients with HZ is rare, due to less and more localised viremia, exudate from open HZ lesions may potentially infect close contacts who have not had varicella or been immunised [10, 320–324].
Intrinsic risk factors
Pregnancy is another immunosuppressed state that may potentiate HZ . Although this seldom occurs, HZ is the most common skin infection that dermatologists encounter in pregnant women, accounting for up to 30% of cases . While challenging to treat, unlike congenital varicella, HZ poses minimal risk to the foetus [330, 331].
Good’s syndrome is a very rare immunodeficiency disease predisposing to HZ .
Common comorbidities of herpes zoster in Asia-Pacific patient populations
Setting (patient number)
Age profile (years)
Proportions with comorbidities (%)
Korea (Park SY 2004) 
Korea (Kim YM 2008) 
China (Yuan LL 2014) 
Philippines (Jara 2010) 
Japan (Kurokawa 2002) 
Thailand (Tunsuriyawong 2005) 
India (Abdul Latheef 2011) 
Taiwan (Jih 2009) 
Taiwan (Hu 2013) 
Taiwan (Wu CY 2010) 
Japan (Kurokawa 2007) 
Quartile range (IQR)
Patients with certain underlying diseases have apparently increased risk of HZ; however, it may be difficult to ascertain whether such relationships are causal, reflect underlying pathology, or are coincidental. In cancer, SLE, and other diseases treated with immunosuppressants, HZ may be largely treatment-related, although the disease too may make an indeterminate contribution to increasing the risk . In others, for example, diabetes and renal disease, impaired CMI may be a common factor. Adjusted for age and other confounding variables, several comorbidities have been identified as independent risk factors for HZ, most notably renal disease, malignancies, and SLE (Fig. 6) [137, 157–167].
The incidence of HZ increases across the spectrum of renal disease, with transplant patients at highest risk followed by peritoneal dialysis and haemodialysis [157, 159, 160, 341–343]. The risk of HZ in haemodialysis is heightened by corticosteroid use, but may be mitigated by iron and vitamin D supplementation [334, 335].
Inflammatory autoimmune diseases
HZ frequently afflicts patients with connective tissue disorders , with double the risk in rheumatoid arthritis . Patients with SLE have impaired CMI and are treated with immunosuppressant anti-inflammatory drugs, which significantly increases their risk of HZ [137, 161, 345, 346], particularly if they have neuropsychiatric manifestations, renal involvement, or receive cyclophosphamide . Likewise, increased risk of HZ associated with inflammatory bowel disease probably reflects iatrogenic immunosuppression in many patients [162, 347].
Cancer patients may be immunosuppressed due to malignancy, its treatment, or both [12, 39, 348]. Risk of HZ is increased in both solid and haematologic cancers [158, 349, 350], especially leukaemia and lymphoma [137, 158].
Both immune dysregulation and corticosteroid therapy may account for increased risk of HZ in chronic obstructive pulmonary disease. Patients taking oral corticosteroids are at the greatest risk .
Peptic ulcer disease
Peptic ulcer disease independently predicts HZ, having excluded confounding effects of anti-inflammatory drugs and Helicobacter pylori infection .
CMI is also diminished in psychiatric disorders. The risk of HZ is increased in patients with affective psychoses, neurotic illness, personality disorders and other mental disorders, especially among those younger than 60 .
Complicating presentations and disease associations
Herpes zoster complication rates in Asia-Pacific patients
Setting (number of patients)
Age profile (years)
Proportions with complications (%)
Post-herpetic neuralgia (months)
Taiwan (Lin 2010) 
Hospitals (2.93% of 672783)
52.5 (neurologic including PHN)
Australia (MacIntyre 2003) 
Korea (Kim YM 2008) 
Korea (Lee 2006) 
Korea (Park 2004) 
Philippines (Jara 2010) 
Thailand (Aunhachoke 2011) 
Hospitals/tertiary centres (180)
Singapore (Oh 1997) 
India (Abdul Latheef 2011) 
Australia (Stein 2009) 
General Practice (379)b
Japan (Akiyama 2000) 
India (Gopal 2010) 
Korea (Son 2011) 
Korea (Min 2007) 
Korea (Kim SH 2008) 
New Zealand (Wallis 2014) 
General Practice (278)
New Zealand (Reid 2014) 
General Practice (339)
Thailand (Tunsuriyawong 2005) 
Singapore (Goh 1997) 
Dermatology outpatients (164)
Japan (Imafuku 2014) 
Taiwan (Tsai TF 2014) 
General Practice & Hospitals (150)
Korea (Song 2014) 
Specialist centres (151)
Japan (Kurokawa 2002) 
Japan (Kurokawa 2007) 
Korea (Cho 2014) 
Taiwan (Jih 2009) 
Korea (Choi 2010) 
Cancer screening (282)
China (Yang 2005) 
Korea (Herr 2002) 
China (Zhu 2009) 
Korea (Cheong 2014) 
China (Song 2002) 
Quartile range (IQR)
Neuropathy, inflammation and secondary complications
HZ causes multifarious complications, especially inflammatory sequelae, which affect up to half or more of hospitalised HZ patients. The most common besides PHN involve the skin, eyes or, less often, ear, nose and throat (Table 5) [11, 12, 15, 26, 30, 102, 104, 136, 340, 354]. Uncommon complications include muscular weakness or paralysis and serious – sometimes life-threatening – cerebral or visceral inflammation. Elderly or immunocompromised individuals are more frequently and often worse affected [30, 96, 340, 370].
The most common and severe complications stem from VZV reactivation in trigeminal ganglion, which is the most frequently affected non-spinal location [11, 12, 23, 26, 29, 34, 371]. In particular, HZ ophthalmicus (HZO) arising from the ophthalmic division accounts for 5% to 25% of HZ cases in Asia-Pacific countries [11, 15, 17, 22, 30, 102, 104, 136, 154, 340, 354] (Table 5). The majority of cases, especially those accompanied by nose eruptions (Hutchinson's sign) [372–375], are complicated by secondary inflammation such as conjunctivitis, keratitis [376–378], scleritis, and uveitis/iridocyclitis [372–374, 379–381]. Such complications can cause glaucoma and are potentially blinding, especially if not treated promptly [379, 382]. However, inflammatory sequelae may not manifest until some time after an HZ episode . Early and intensive antiviral therapy is particularly important for patients with HIV/AIDS, who tend to have worse and treatment-refractory inflammation, with resultant vision loss [384–386].
Molecular diagnostic techniques have revealed VZV reactivation to be a predominant cause of anterior uveitis in South and East Asian countries [387–389], with significantly increased risk within 1 year following HZ, especially HZO . VZV is also a major cause of acute retinal necrosis [391–397] in the region, and of progressive outer retinal necrosis, which is usually seen in severely immunocompromised patients [398–402]. Both conditions have particularly poor visual outcomes, even when treated appropriately [375, 391, 392, 397, 399, 403–407].
Less common ocular complications include, corneal endotheliitis , retinochoroiditis , optic neuritis [409–411], oculomotor palsy , dacryoadenitis [412, 413], superior orbital fissure syndrome , orbital apex syndrome [415, 416], and central retinal vein occlusion .
Ear, nose and throat
Occasionally, VZV reactivation in the facial nerve genicular ganglion causes HZ oticus (Ramsay Hunt syndrome) [418, 419]. Patients often have multiple neuropathies and diverse symptoms, depending on the cranial and facial nerve branches involved. As elsewhere, the characteristic triad is facial palsy, auricular rash and ear pain [418, 420–422]; however, some cases affect the tongue, soft palate, or throat [423, 424], and the rash may precede facial paralysis, not appear until afterwards , or be absent . Many patients experience hearing loss and vestibulo-cochlear symptoms such as tinnitus and vertigo [418, 420, 425, 426]. The seventh and eighth cranial nerves are most commonly affected [420, 427], but many atypical cranial neuropathies have also been identified [428–431]; Ramsay Hunt syndrome has been associated with dysphonia [46, 424, 429, 432, 433], laryngitis [434, 435], loss of taste , chronic cough , hiccups [435, 438], dysphagia [46, 424, 429, 439], and persistent vomiting . Other rare complications include jugular foramen syndrome  and non-facial neuromotor deficits . In addition to Ramsay Hunt syndrome, zoster sine herpete is increasingly recognised as a major aetiologic factor in idiopathic Bell’s palsy [442–444] and Ménière's disease [445, 446].
HZ oticus generally responds to prompt antiviral therapy, with good outcomes [421, 430]; however, half of patients may not recover fully from facial palsy [420, 421], with even lower rates among those who are older , have multiple cranial neuropathies , or are not treated . The diversity of manifestations, often occurring sine herpete, creates potential for misdiagnosis . It is vital for clinicians to remain alert to the possibility of HZ, so that treatment can begin early enough to avoid potentially life-threatening sequelae of VZV reactivation in the head and/or neck [438, 447].
Fewer than 5% of HZ cases in Asian patients cause motor neuropathy [448–450]. Though more common in the elderly or immunocompromised [450, 451], such complications also affect immunocompetent individuals [452, 453]. Among 711 Korean HZ patients, 2.1% had neuromotor weakness, predominantly affecting cranial rather than spinal nerves . The incidence was 0.8% among 1432 Japanese patients  and 3% in an Indian cohort . Such complications may arise before skin lesions appear and are likely underdiagnosed because they are masked by overriding pain [455, 456]; they may also occur some time after HZ onset [452, 457, 458]. Other presentations include gastrointestinal or bladder dysfunction , myelitis [450, 459–461], and myositis . VZV infection is implicated in the aetiology of Guillain-Barré syndrome [463–465].
Face and eye
Paresis of the ipsilateral shoulder or arm [473–477], occurs in 3–5% of HZ cases, but is underdiagnosed [478, 479]. Some cases are due to brachial plexopathy [480, 481], and others to Brown-Séquard hemiplegia [460, 482]. Lower limb neuropathy may manifest as foot drop [449, 483], and HZ paresis-induced femoral fracture has been reported .
Trunk and abdomen
Cervical myelitis can cause diaphragmatic paralysis with resultant dyspnoea [457, 485–487]. Segmental paresis may cause abdominal protrusion or pseudohernia [488–492], which are associated with gastrointestinal complications, notably constipation due to intestinal pseudo-obstruction or colonic ileus [488, 493–496].
Voiding dysfunction associated with sacral HZ is uncommon but not rare, especially among immunocompromised patients . The incidence among 423 Taiwanese HZ patients was 4% overall, and 29% among those with lumbosacral HZ . Urinary problems include neuropathic bladder , loss of voiding sensation  and occasional acute urinary retention [461, 501–503]. Other complications include faecal incontinence  rectal ulcer  and sciatica .
Though rare, vasculitic cerebral inflammation is the most serious neurologic complication of HZ; VZV from intracranial branches of the trigeminal nerve that invades and inflames the carotid artery or its branches, may cause fatal strokes [9, 10].
Cerebral arteritis arising from HZ, especially HZO, significantly increases the risk of thromboembolic or haemorrhagic strokes [507, 508]. Those affected may have no visible lesions [509, 510] and strokes may be delayed [511–516] or occur without characteristic risk factors or symptoms [512, 513, 517, 518], leading HZ-associated stroke to be underdiagnosed [514, 519]. HIV/AIDS might be suspected in otherwise healthy younger individuals [518, 520].
Rare but severe and sometimes fatal neurologic complications include meningitis or meningo-encephalitis [521–526], cerebellitis , and encephalitis [528, 529]. Other reports include posterior reversible encephalopathy syndrome , CLIPPERS syndrome , and fatal meningo-encephalomyelitis . Again, those affected are generally immunocompromised [9, 10], although accruing evidence suggests that such complications affect young and/or immunocompetent individuals more often than was supposed [521, 533–538].
Cases of Horner’s syndrome and related cranial nerve palsies [539–542] have been attributed to HZO-induced arteritis and VZV meningitis . Reported HZ retinopathies include visual loss due to central retinal artery occlusion and vasculitic chorioretinopathy [404, 544, 545].
Intriguing evidence hints at a link between HZ and cardiovascular disease in Asia. There are modestly elevated risks of acute coronary syndrome, arrhythmia and coronary artery disease following HZ [546, 547]. Herpetic infections may also be associated with atherosclerosis and thrombosis , with reports of HZ-associated deep vein thrombosis  and peripheral vascular disease . Myocarditis  and unexplained recurrent asystole  following HZ have also been reported. Interestingly, however, Japanese patients with prior HZ had lower blood pressure than those with no history .
The most common dermatologic complications are secondary infections but numerous others have been described . Rare complications include folliculitis, syringitis, and vasculitis [552–554]. HZ can also cause hair loss [555, 556].
Secondary infections complicate up to 30% of HZ cases , rising to 60% in vulnerable hospitalised patients . The most common are staphylococcus or streptococcus superinfections [9, 10]. Other opportunistic organisms include moraxella , and aspergillus . Bacterial infections are more likely in patients with diabetes [559, 560] and potentially serious, with necrotising fasciitis reported in one immunocompromised patient . Immunocompromised patients, particularly those with HIV/AIDS, may rarely become reinfected by varicella despite a history of HZ .
HZ may render affected skin susceptible to other infections or dermatoses, for example, moloscum contagiosum, mycosis fungoides , erythema multiforme , and psoriasis [564, 565]. Diverse ‘isotopic’ responses at healed HZ sites include: vitiligo , fungal granuloma , furuncles , granulomatous reactions [569–574], erythemas [575–578], lichen planus [579, 580], morphea and bullae [581–583], perforating collagenosis [584, 585], keratolysis  and sarcoidosis [587, 588], reticulohystiocytosis , nodular degeneration [590, 591], verrucous hyperplasia , mucinosis , urticaria , prurigo nodularis , graft-versus-host reaction , drug-induced eruption , adenocarcinoma , leukaemia cutis , Kaposi’s sarcoma , and tufted angioma .
Emerging evidence from Taiwan and Japan suggests that patients with HZ are at increased subsequent risk of cardiovascular disease [546, 547], lymphoma  and other cancers [466, 612, 613], renal failure , SLE , multiple sclerosis , chronic fatigue syndrome , depression [618, 619] and erectile dysfunction ; however, the causality and significance of these associations remains unclear. Prevalent comorbidities such as metabolic syndrome disorders probably contribute to cardiovascular risk , while immunosuppression may underlie other conditions. Like HZ, kidney disease [160, 335], cancer [466, 612, 621, 622], and depression  are also associated with immunosuppression, and HZ may occur coincidentally either before or after these conditions manifest.
Anecdotal reports implicate VZV reactivation in rare conditions such as inappropriate secretion of antidiuretic hormone [85, 87, 623–626], drug-induced hypersensitivity syndrome , mononucleosis syndrome , thrombocytopenia , and graft-versus-host disease .
As in the West, HZ-associated pain, morbidity and debility, result in heavy healthcare utilisation, especially among elderly patients, which imposes major burdens on healthcare systems and incurs substantial socio-economic costs in Asia-Pacific countries [20, 25, 30, 96, 102, 104, 136, 137, 140]. Although uncomplicated cases can usually be treated in community or outpatient settings, this usually entails several visits [20, 30, 96, 102]; Korean HZ patients averaged seven visits to a primary physician , and among 150 elderly Taiwanese patients, more than 80% consulted a doctor, with 20% hospitalised .
Herpes zoster hospitalisation rates, durations and associated healthcare costs in Asia-Pacific countries
Age profile (years)
Hospitalisations (100000 person years)
Hospitalisation duration (days)
Healthcare costs (US$ equivalent)c
Annual total (millions)
Taiwan (Lin 2010) 
7.7 in 2000 → 9.8 in 2004 (NT$ 319,000,000)
Taiwan (Jih 2009) 
0.669773 (NT$ 14,147,543)
59.5% of total
59.5% of total
Korea (Cheong 2014) 
Australia (Stein 2009) 
Thailand (Aunhachoke 2011) 
90.4 (by 180 days follow-up)
~1.1% per capita income
Korea (Choi WS) 
75.9 increasing by 14–20% per year to 143.8
Australia (MacIntyre 2003) 
53.0% of total
Korea (Song 2014) 
Korea (Kim YJ) 
Australia (Carville 2010) 
Australia (Araújo 2007) 
Australia (Heywood 2014) 
Accordingly, HZ-related healthcare costs also increase proportionally with patients’ age and parallel rising incidence [136, 137]. Total expenditure in Taiwan rose by 1.22-fold from US$7.7 million in 2000 to $US 9.8 million in 2004 , and in Korea by 20% between 2003 and 2007 (Table 6) . Direct healthcare costs in Thailand are equivalent to 1.1% of annual per capita income, a similar ratio to that in developed nations .
HZ in the Asia-Pacific region evidently imposes very substantial burdens on both patients and the wider community, strongly supporting the case for early intervention and prevention to reduce both HZ-related morbidity and associated healthcare expenditure [20, 25, 30, 96, 102, 104, 140].
Management and prevention
Routine HZ management in Asia-Pacific is the same as elsewhere, mainly relying on antiviral and analgesic drugs to reduce the severity and duration of acute herpetic rash and pain, which may in turn decrease the risk and intensity of PHN [643, 644].
Standard care entails aciclovir, valaciclovir, or famciclovir for 7 days . These are most effective if commenced within 3 days of onset  but as starting later may still be beneficial, patients with HZO, who are immunocompromised, have disseminated HZ, or are at high risk for PHN, should start antiviral therapy even beyond 72 hours [643–646]. Topical or oral aciclovir are effective in most mild-moderate HZ, including HZO [647–651]; nevertheless aciclovir is least favoured nowadays because its lower bioavailability necessitates more frequent dosing [9, 644, 652]. Though comparative data are sparse [643, 652], Asian studies support the use of other antivirals.
A meta-analysis including data from Taiwan [653, 654] and China, found valaciclovir and famciclovir superior to aciclovir in reducing HZ-associated pain, with comparable safety . Valaciclovir resolves pain significantly faster than aciclovir [31, 653–655], while famciclovir has comparable efficacy but fewer adverse effects, and may also be more cost-effective [656, 657]. Penciclovir is also effective at lower doses than aciclovir, with better safety . Specifically, aciclovir or its prodrug valaciclovir have been associated with neurotoxicity, and nephrotoxicity in East Asian patients with renal impairment [659–669], whereas famciclovir was safe and effective in patients with renal dysfunction [670, 671]. Treating HZ keratopathy with aciclovir ointment has been reported to cause superficial punctate keratopathy . Ganciclovir may be a more effective alternative [673, 674], especially in aciclovir-resistant acute retinal necrosis ; success with intravitreal foscarnet following acyclovir failure has also been reported . Valaciclovir and famciclovir are thought to have similar efficacy [643, 677], but Japanese researchers reported significantly faster pain relief with famciclovir . In Caucasians, sirovudine treated acute HZ as safely and effectively as aciclovir but with fewer recurrences ; however, sirovudine has potentially fatal interactions with 5-fluorouracil prodrugs, which killed 18 Japanese cancer patients .
Pain control is crucial to HZ management, not only for acute analgesia, but also because pain severity predicts PHN [9, 643, 644]. Although prompt antiviral therapy reduces acute HZ-associated pain, an updated meta-analysis concluded that aciclovir does not reduce the incidence of PHN and found insufficient evidence to evaluate the effect of other antiviral agents . In practice, antiviral therapy is usually given concomitantly with corticosteroids or analgesics, according to the degree of pain.
Oral corticosteroids relieve pain, accelerate lesion healing and hasten functional recovery; however, being immunosuppressive they cannot be given without concomitant antiviral therapy. Moreover, corticosteroids should be used with caution in patients with common comorbidities such as diabetes and hypertension and do not prevent or relieve PHN [643, 645, 646]. Nevertheless, corticosteroid injections have successfully treated cases of Ramsay Hunt syndrome and refractory PHN in Chinese patients [682, 683].
Pain relief should start early and be intensified as necessary during acute HZ to control pain and reduce the likelihood of developing PHN, which is much harder to treat [656, 684, 685]. Pain management steps-up from first-line acetaminophen or non-steroidal anti-inflammatory drugs to opioid narcotics for moderate-to-severe pain, to which anticonvulsants, tricyclic antidepressants or corticosteroids are added if pain remains uncontrolled . The same second- and third-line analgesics are used to treat PHN if topical agents prove ineffective [643, 646].
Indian physicians have reported rapid and effective pain relief with topical acetylsalicylic acid dissolved in chloroform . Others confirmed the efficacy of the anticonvulsants pregabalin and gabapentin for relieving acute herpetic pain [687, 688], and found pregabalin superior to amitriptyline for PHN . Compared with placebo, pregabalin relieved PHN and was also associated with decreased sleep interference and significant improvements in health-related QoL . Gabapentin is another effective and well-tolerated treatment for PHN  and combined with morphine in another trial, reduced pain more than either agent alone . Chinese investigators found oxycodone-acetaminophen effective, safe and superior to other analgesics in HZ and PHN [692–696]. Reports from Australia, Japan, New Zealand and Taiwan have affirmed the efficacy of topical [697–699] or injected lidocaine [700, 701]. Transdermal fentanyl was found to be more effective than tramadol, providing excellent pain relief in HZ and PHN and improving QoL, both alone [702, 703] and combined with clodine . Other experimental therapies with good reported outcomes in patients from Asia-Pacific countries include: topical interferon alpha [705, 706], adenine arabinoside (vidarabine) [707, 708], povidone-iodine , transdermal ribavirin , bromovinyl deoxyuridine (brivudin) , intravenous prostaglandin E1 [355, 712–715], the anticoagulant argatroban ; the tricyclic antidepressant milnacipran , human immunoglobulin , injected methylcobalamin , and botulinum toxin .
Nerve blockade is increasingly popular for treating intractable PHN or preventing PHN by reducing severe pain, particularly in East Asia [363, 721–742]; ambulatory patient-controlled systems have been successful in Taiwan [743, 744]. However, the true efficacy of nerve blocks is difficult to quantify because many trials were uncontrolled . Furthermore, epidural injections require utmost caution due to the potential for infection and/or life-threatening complications [745–755]. An implanted injection port may lessen the risk of infection .
Neurosurgery may trigger HZ [269–271] and though neuroablation has also been used, its efficacy is unproven and it may exacerbate PHN ; neuromodulation may provide an alternative but needs further investigation [758, 759].
Alternative treatment modalities
Asia-Pacific authors have contributed substantial literature on alternative HZ therapies (Additional file 1). Success has been reported with herbal decoctions, acupuncture and other traditional Chinese medicine techniques, energy-based modalities, and combination therapies. Treatments evaluated in intractable HZ and PHN, include Ganoderma lucidum [760, 761], Keishikajutsubuto and Bushi-matsu , bee venom , intravenous vitamin C , computed tomography-guided radiofrequency thermo-coagulation , spinal cord stimulation , ultrasound-guided pulsed radiofrequency , and scrambler therapy . Although many studies found these alternatives superior to conventional medicine, the strength of this evidence is dubious – due to conceptual differences between traditional Asian and Western medicine, many such studies do not conform to conventional evidence-based precepts [768–770].
Unmet treatment needs
Despite an armamentarium of potentially effective medications, current therapies have limitations and are not used to best advantage in older patients, who bear the brunt of HZ . In particular, many patients start therapy too late, the optimal combination of therapies remains uncertain, antiviral agents are underprescribed [22, 645, 771], and even with prompt intervention a substantial proportion remain refractory to treatment; up to 20% of patients with PHN still have persistent neuralgia after 6 months (Table 5) [18–20, 23, 28, 359, 771]. Aciclovir-resistant ocular VZV infections have been encountered [675, 676, 772, 773].
Given the substantial and rising burden of HZ and formidable treatment challenges facing physicians in the Asia-Pacific region, especially among elderly, immunocompromised or other high risk adults, such as those with renal disease, prevention is both rational and appealing [20, 25, 94–96, 104, 136, 140, 144–147, 160, 644]. Accordingly, investigators have evaluated HZ prophylaxis with antiviral drugs or vaccines.
Antiviral prophylaxis in high-risk patients
HZ is a very common complication following HSCT [170, 774]. Long-term prophylaxis with low-dose aciclovir [775–778] or valaciclovir  significantly reduces the incidence of VZV reactivation and serious complications, and is recommended for the duration of immunotherapy and continuing through 1 year after HSCT [776, 778]. Such prophylaxis also prevents HZ in patients receiving bortezomib [780, 781]. Similarly, no bone marrow transplant recipients developed HZ during 3–6 months of low-dose aciclovir and ganciclovir therapy; however, rapid onset of HZ after antiviral therapy was discontinued highlighted the need for ongoing prophylaxis . Immunisation against VZV may be necessary to preclude HZ in high-risk patients ; therefore, Asian researchers have evaluated the potential of HZ prophylaxis with varicella vaccines.
A survey of Japanese paediatricians, who might have enhanced immunity through VZV re-exposures, confirmed lower incidence of HZ than the general population, suggesting that varicella vaccine may likewise protect against HZ . Also in Japan, immunisation with live varicella vaccine (Oka/BIKEN) enhanced CMI to VZV in adults age ≥50 years [783, 784], and in subjects aged 60–70 with or without diabetes . A case of recurrent HZO cured by varicella vaccination was also reported . In studies that evaluated live-attenuated VZV vaccine in HSCT [774, 787], Oka/RIT (Varilrix™ Glaxo-SmithKline Biologicals, Rixensart, Belgium) was safe but poorly immunogenic. A systematic review concluded that although inactivated VZV vaccine may reduce HZ severity in stem cell transplant recipients, more research was required . Thus, alternative approaches to preventing HZ in such patients are probably needed .
During a 20-year endeavour to develop the first specific HZ vaccine, researchers reformulated Oka/Merck varicella vaccine (Varivax® Merck & Co. Inc., Whitehouse Station, NJ, USA.) to produce a higher-titre live-attenuated VZV vaccine – Zostavax® (Merck & Co. Inc.) [10, 789]. In the culminating Shingles Prevention Study (SPS), Zostavax® immunisation reduced the incidence of HZ among adults ≥60 years old by 51%, PHN by 67% and the HZ-related burden of illness by 61%, as well as improving QoL and performance of daily activities in subjects who developed HZ . The US Food and Drug Administration licenced Zostavax® in 2006 ; it was also approved by the European Medicines Agency  and subsequently by authorities in Australia  New Zealand , Korea [790, 791], Malaysia , and other Asian countries [793–796]. The US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP), recommends routine vaccination for all non-contraindicated persons age ≥60 years; importantly though, Zostavax® is not indicated to treat extant HZ or PHN . An independent review of SPS concluded that there is insufficient proof that Zostavax® prevents PHN beyond reducing the incidence of HZ. Further, since SPS patients were predominantly Caucasian, its findings might not apply to other races .
Zostavax® in Asia-Pacific
Production shortfalls of Zostavax® after initial licensure restricted its supply [1, 2]. Though since resolved, this issue affected vaccine availability and uptake in Asia-Pacific countries . For example, 2011 vaccination rates among Australian inpatients in 2011 were 34% for HZ, compared with 52% for pneumococcal vaccine and 64% for influenza . This explains the scarcity of Asian data on Zostavax®. One pilot study of 21 healthy adults ≥30 years old, including eight Filipinos, found Zostavax® to be immunogenic and generally well-tolerated .
The substantial economic burden of HZ includes direct healthcare costs as well as indirect costs of disability and lost productivity [10, 30, 140]. US and European researchers have modelled the pharmaco-economics of HZ vaccination. US estimates of cost per quality-adjusted life-years gained (QALY), varied widely depending on the assumptions used. Routine immunisation at age 70 or 60 cost US$ 37000 and US$ 86000 respectively, within the range of standard thresholds, whereas the estimated cost of US$ 287000 at age 50 was deemed too high . Analyses in European countries predicted that vaccinating adults above the ages of 50, 60, 65 or aged 70–79 would be cost-effective, with high likelihood of not exceeding accepted thresholds of £ 30000 in the United Kingdom or € 30000 in Belgium . A systematic review of 11 US and European studies concluded that vaccination at age 65–70 would probably be cost-effective in terms of QALYs gained, assuming it confers more than 10–15 years’ protection against PHN ; however, cost-effectiveness data from high-income countries may not apply worldwide, because healthcare provision and costs differ considerably between nations [801, 802]. Although high and rising healthcare costs of treating HZ documented in several Asia-Pacific countries [30, 104, 136, 137, 140] suggest that it would probably be no less cost-effective to immunise elders from this region than others, specific pharmacoeconomic data are lacking [790, 802]; such analyses are needed urgently to resolve current uncertainties and inform evidence-based decision-making by healthcare funders and providers.
HZ immunisation guidelines and recommendations
Asia-Pacific guidelines for immunisation against herpes zoster
Year (last update)
The Australian Immunisation Handbook
Technical Advisory Group on Immunisation
Australia & New Zealand 
Immunisation of Older People
Australia & New Zealand Society for Geriatric Medicine
Medicine Update. Adult Immunization
Association of Physicians of India
Adult Immunization Schedule
Specialist Doctors Association of Indonesia
Position Statement on Vaccination Against the Herpes Zoster Virus in Older Adults
Malaysian Society of Geriatric Medicine
New Zealand 
New Zealand Ministry of Health
Handbook on Adult Immunization for Filipinos
Philippine Society for Microbiology and Infectious Diseases
South Korea 
Recommended Immunization Schedule for Adults in Korea
Korean Society of Infectious Diseases
Clinical Handbook for Adult Immunization
Taiwan Association of Family Medicine
Recommended Adult and Elderly Immunization Schedule
Thailand Royal College of Physicians
Concordance between herpes zoster immunisation recommendations from US ACIP and Asia-Pacific countries
Indications and administration
• Routine immunisation with one dose of HZ vaccine for all persons age ≥60: – With or without prior HZ – With chronic medical conditions (eg, chronic kidney disease, diabetes, rheumatoid arthritis, lung disease), except those listed as contraindications or precautions
• HZ vaccine can be co-administered with other indicated adult vaccines, eg, influenza
Unlicensed categories/ purposes
• Persons immunised with varicella zoster vaccine
• Persons younger than the minimum recommended or optional age threshold
• HZ vaccine is not to be used to treat existing HZ or its complications
• Moderate/severe acute illness
• Anticipated immunosuppression
• Anti-herpetic pharmacotherapy
• Hypersensitivity to vaccine components
• Morbid or medical immunosuppression or immunodeficiency: – HIV/AIDS – Transplant recipients – Systemic immunosuppressive therapy (including high-dose steroids and recombinant immune modulators
Ours is the most comprehensive audit yet of HZ in the Asia-Pacific region. We have reviewed almost every available paper published on the subject over 21 years since 1994 in 14 countries whose populations constitute the majority of not only Asians, but indeed the global population. The information collated provides a valuable resource and reference by which to gauge future progress.
Knowledge and data gaps
Contrary to a preconception that there may be a dearth of Asian data, we discovered a wealth of evidence on all aspects of HZ. However, our review does affirm that Asian data are patchy; in particular, there is very little information from South-East Asian populations numbering hundreds of millions, which probably reflects pragmatic healthcare imperatives in resource-limited settings . Limiting the scope of the survey to 21 years may have missed epidemiology data published prior to 1994. The review may have excluded some relevant articles which did not specify that VZV infection was reactivated. It is also possible that some articles with no country affiliation field in the databases searched may have been overlooked; however, searching several databases reduced this possibility. Epidemiology data from Indonesia, Malaysia, the Philippines, and Vietnam are needed to provide a more balanced picture. There are also limited Asian data on the safety and efficacy of the HZ vaccine and, in particular, its cost-effectiveness [137, 140, 790, 802].
Data gaps notwithstanding, there is compelling evidence to conclude that the epidemiology and risk factors for HZ in the Asia-Pacific region are not remarkably different from those in Western populations . However, with a vastly larger absolute aged population, Asia bears a unique burden of HZ. The estimated number of Asians1 age >60 in 2015 is 489,397,421, which by 2035 will nearly double to 924,520,454 . Assuming an annual incidence of HZ in unvaccinated individuals of approximately 12/1000 person-years [136, 137], this equates to approximately 16089 new HZ cases daily in 2015 and 30395 in 2035, more than half of which might be prevented by HZ immunisation. Data affirming rising incidence of HZ in countries across Asia-Pacific bear out these projections. Consequently, HZ in the Asia-Pacific region exacts huge and increasing tolls of morbidity, debility and diminished life quality that incur significant healthcare expenditure and indirect socioeconomic costs [20, 25, 30, 96, 104, 136, 137, 140].
This review also highlights that HZ is uniquely complex among infectious diseases, often complicated and defies disciplinary boundaries. Despite a plethora of conventional and alternative treatments, none is singularly effective ; current approaches can go only so far to alleviating the disease burden, especially among the elderly who constitute most patients, and then at considerable expense . Thus, the rationale for prevention is very strong [20, 102, 145]. Yet although a specific HZ vaccine is available and recommended by immunisation guidelines in many countries, it remains underused. This typifies how preventive healthcare for the elderly continues to be neglected in Asia, despite repeated calls to make this a higher public health priority [3, 4, 6]. It is more urgent now than ever to address this situation.
Call to action
We look forward to being able to report in future that advances in preventive healthcare have alleviated the growing burden of HZ in the Asia-Pacific region. This audit is just a beginning – realising this ambition will be impossible without redoubled efforts by the medical fraternity, healthcare authorities and all other stakeholders to change prevailing mindsets and afford higher priority to adult immunisation in general and HZ in particular. We urge all concerned to heed this call to action.
Afghanistan, Bangladesh, Bhutan, Brunei, Burma, Cambodia, China, Hong Kong, India, Indonesia, Iran, Japan, Laos, Macau, Malaysia, Maldives, Mongolia, Nepal, North Korea, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste, Vietnam.
Advisory Committee on Immunization Practices
Acquired immunodeficiency syndrome
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids
Highly-active antiretroviral therapy
Human immunodeficiency virus
Haematopoietic stem cell transplant
Herpes zoster ophthalmicus
Quality of life
Systemic lupus erythematosus
Shingles Prevention Study
Varicella zoster virus
World Health Organization
MSD funded preparation of the manuscript, but had no role in designing the study, data collection or analysis, drafting or approving the manuscript, or the decision to submit for publication. The authors thank Dr. David Neil (PhD), of Content Ed Net (Taiwan) for providing professional medical writing services, which were remunerated by Merck Sharp & Dohme (I.A.) Corp, Taiwan.
The authors received no specific research funding for the work described in this manuscript.
Availability of data and materials
All supporting data are either contained within the manuscript or were excerpted from the sources cited, and can be shared upon request.
LKC conceived and coordinated the study, acquired and interpreted data, and revised manuscript drafts for important intellectual content. HA, LYC, SD, BD, TK, XL, DM, JYP, PJHP, SR, TT, and CWW, refined the review protocol, provided and/or reviewed or interpreted data, and revised manuscript drafts for important intellectual content. MYC, KTK, HNL, EMFL, CKL, LNP, and ERSP, contributed to refining the review protocol, and reviewed data and manuscript drafts. All authors read and approved the final manuscript.
The authors are members of The Asia-Pacific Working Group for Herpes Zoster, which is supported financially by Merck Sharp & Dohme (I.A.) Corp. (MSD), Taiwan, and received honoraria for consultancy services in this capacity. The authors declare no other competing interests besides membership of this MSD Advisory Board.
Consent for publication
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Harpaz R, Hales CM, Bialek S. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR Morb Mortal Wkly Rep. 2011;60:1528.Google Scholar
- Heywood AE, Wang H, Macartney KK, McIntyre P. Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study. Bull World Health Organ. 2014;92:593–604.
- Isahak I. Steering Committee for Prevention and Control of Infectious Diseases in Asia. Adult immunization—a neglected issue in Southeast Asia. Southeast Asian J Trop Med Public Health. 2000;31:173–84.
- Verma R, Khanna P, Chawla S. Vaccines for the elderly need to be introduced into the immunization program in India. Hum Vaccin Immunother. 2014;10:2468–70.
- Woodward M. Immunisation of older people. J Pharm Pract Res. 2012;42:316–22.
- Wong SY. Adult vaccination update 2014. The Singapore Fam Physician. 2014;40:27–32.
- Araújo LQ, MacIntyre CR, Vujacich C. Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America. Herpes. 2007;14(Suppl 2):40–4.
- Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th ed (updated June 2015). Canberra: Australian Government Department of Health. 2015. http://www.health.gov.au/internet/immunise/publishing.nsf/content/7B28E87511E08905CA257D4D001DB1F8/$File/Aus-Imm-Handbook.pdf. Accessed 17 Jan 2017.
- Thomas J. Herpes zoster: Complications and management. J Pak Assoc Dermatol. 2004;14:237–43.Google Scholar
- Harpaz R, Ortega-Saznchez IR, Seward JF. Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1–30.PubMedGoogle Scholar
- Kim YM, Lee SY, Lee JS, Park YL, Whang KU, Cho MK, et al. Epidemiological and clinical study on herpes zoster in the Province of Chungcheongnam-do (2004–2006). Korean J Dermatol. 2008;46:1488–94.Google Scholar
- Abdul Latheef EN, Pavithran K. Herpes zoster: a clinical study in 205 patients. Indian J Dermatol. 2011;56:529–32.PubMedPubMed CentralView ArticleGoogle Scholar
- Shukuwa T, Chen WY, Kobayashi A. Statistical analysis of herpes zoster observed at Sasebo City General Hospital. Nishinihon J Dermatol. 2002;64:477–82.View ArticleGoogle Scholar
- Naveen KN, Tophakane RS, Hanumanthayya K, Pv B, Pai VV. A study of HIV seropositivity with various clinical manifestation of herpes zoster among patients from Karnataka, India. Dermatol Online J. 2011;17:3.PubMedGoogle Scholar
- Jara MFA, Roa FC. The clinical presentation of herpes zoster patients and predictors of postherpetic neuralgia: A 5-year retrospective study at the section of dermatology, University of the Philippines - Philippine General Hospital. J Phil Dermatol Soc. 2010;19:8–12.Google Scholar
- Leung AYH, Yuen KY, Cheng VCC, Lie AKW, Liang R, Kwong YL. Clinical characteristics of and risk factors for herpes zoster after hematopoietic stem cell transplantation. Haematologica. 2002;87:444–6.PubMedGoogle Scholar
- Reid JS, Ah WB. Herpes zoster (shingles) at a large New Zealand general practice: incidence over 5 years. N Z Med J. 2014;127:56–60.PubMedGoogle Scholar
- Goh CL, Khoo L. A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. Int J Dermatol. 1997;36:667–72.PubMedView ArticleGoogle Scholar
- Song JY, Chung BS, Choi KC, Shin BS. A 5-year period clinical observation on herpes zoster and the incidence of postherpetic neuralgia (2002–2006); a comparative analysis with the historical control group of a previous study (1995–1999). Korean J Dermatol. 2008;46:431–6.Google Scholar
- Tsai TF, Yao CA, Yu HS, Lan CC, Chao SC, Yang JH, et al. Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in Taiwan: a prospective observational study. Int J Dermatol. 2015;54:529–36.PubMedView ArticleGoogle Scholar
- Song T. Statistical analysis of 522 cases of patient with herpes-zoster. Med J Wuhan Univ. 2002;23:379–82.Google Scholar
- Wallis KA, Hood LJ, Rao K. Herpes zoster: when do patients present and who gets antiviral treatment? J Prim Health Care. 2014;6:108–13.PubMedGoogle Scholar
- Kurokawa I, Kumano K, Murakawa K. Clinical correlates of prolonged pain in Japanese patients with acute herpes zoster. J Int Med Res. 2002;30:56–65.PubMedView ArticleGoogle Scholar
- Kang CI, Choi CM, Hong SS, Kim HB, Kim NJ, Oh MD, et al. The incidence of herpes zoster in otherwise healthy young soldiers of Korean army. Infect Chemother. 2006;38:45–6.Google Scholar
- Song H, Lee J, Lee M, Choi WS, Choi JH, Lee MS, et al. Burden of illness, quality of life, and healthcare utilization among patients with herpes zoster in South Korea: a prospective clinical-epidemiological study. Int J Infect Dis. 2014;20:23–30.PubMedView ArticleGoogle Scholar
- Park SY, Kim JY, Kim CD, Kim CW, Lee KS. A clinical study on herpes zoster during the last 10-year-period (1994–2003). Korean J Dermatol. 2004;42:1531–5.Google Scholar
- Das AL, Sayal SK, Gupta CM, Chatterjee M. Herpes zoster in patients with HIV infection. Indian J Dermatol Venereol Leprol. 1997;63:101–4.PubMedGoogle Scholar
- Kurokawa I, Murakawa K, Kumano K. The change in zoster-associated pain treated with oral valaciclovir in immunocompetent patients with acute herpes zoster. Int J Clin Pract. 2007;61:1223–9.PubMedView ArticleGoogle Scholar
- Sawhney MPS, Sharma YK, Sayal SK. Mode of detection of HIV infection - A retrospective study of 612 cases. Med J Armed Forces India. 2005;61:220–3.PubMedPubMed CentralView ArticleGoogle Scholar
- Aunhachoke K, Bussaratid V, Chirachanakul P, Chua-Intra B, Dhitavat J, Jaisathaporn K, et al. Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand. Int J Dermatol. 2011;50:428–35.PubMedView ArticleGoogle Scholar
- Achar A, Chakraborty PP, Ghosh T, Naskar B, Guharay T, Bisai S. Clinical efficacy and tolerability of valacyclovir versus acyclovir in treatment of herpes zoster. Iran J Dermatol. 2011;14:52–7.Google Scholar
- Kim CG, Na CH, Choi KC, Shin BS. A comparative study of the clinical findings associated with herpes zoster and according to age. Korean J Dermatol. 2009;47:1338–44.Google Scholar
- Kim HJ, Sung HC, Kim DW, Lee WJ, Lee SJ, Na GY. Clinical features of herpes zoster according to immune state. Korean J Dermatol. 2006;44:149–56.Google Scholar
- Cockburn DM, Douglas IS. Herpes zoster opthalmicus. Clin Exp Optom. 2000;83:59–64.PubMedView ArticleGoogle Scholar
- Naveen KN, Pradeep AV, Kumar JS, Hegde SP, Pai VV, Athanikar SB. Herpes zoster affecting all three divisions of trigeminal nerve in an immunocompetent male: a rare presentation. Indian J Dermatol. 2014;59:423.Google Scholar
- Sangeeta N, Robindro Singh W, Brajach SO. Herpes zoster in a healthy adult: Report of a case with oro-cutaneous presentations. JMS J Med Soc. 2011;25:99–101.Google Scholar
- Watanabe K, Funaki M. Images in clinical medicine: Zoster of the tympanic membrane. N Engl J Med. 2011;365:e40.PubMedView ArticleGoogle Scholar
- Hong SB, Lee JW, Chang SG, Lee MH, Haw CR. Herpes zoster of the penis. Korean J Urol. 2005;46:1001–3.Google Scholar
- Gopalan V, Nair RG, Pillai S, Oberholzer T. Genital herpes zoster as a consequence of cancer chemotherapy-induced immunosuppression: report of a case. J Infect Chemother. 2012;18:955–7.PubMedView ArticleGoogle Scholar
- Watanabe D, Kuhara T, Ishida N, Takama H, Tamada Y, Matsumoto Y. Herpes zoster of the nipple: rapid DNA-based diagnosis by the loop-mediated isothermal amplification method. Int J STD AIDS. 2010;21:66–7.PubMedView ArticleGoogle Scholar
- Izu K, Yamamoto O, Yasumoto S, Hashimoto T, Sata T, Tokura Y. Herpes zoster occurring as a solitary nodule on the index finger. Br J Dermatol. 2004;150:365–6.PubMedView ArticleGoogle Scholar
- Chen WH, Li TH, Lee LH, Huang CC. Varicella-zoster virus infection and nummular headache: a possible association with epicranial neuralgia. Intern Med. 2012;51:2439–41.PubMedView ArticleGoogle Scholar
- Hon C, Au WY, Cheng VC. Ophthalmic zoster sine herpete presenting as oculomotor palsy after marrow transplantation for acute myeloid leukemia. Haematologica. 2005;90 Suppl 12:EIM04.PubMedGoogle Scholar
- Kim YH, Choi IJ, Kim HM, Ban JH, Cho CH, Ahn JH. Bilateral simultaneous facial nerve palsy: clinical analysis in seven cases. Otol Neurotol. 2008;29:397–400.PubMedView ArticleGoogle Scholar
- Furuta Y, Fukuda S, Suzuki S, Takasu T, Inuyama Y, Nagashima K. Detection of varicella-zoster virus DNA in patients with acute peripheral facial palsy by the polymerase chain reaction, and its use for early diagnosis of zoster sine herpete. J Med Virol. 1997;52:316–9.PubMedView ArticleGoogle Scholar
- Fujiwara K, Furuta Y, Fukuda S. A case of associated laryngeal paralysis caused by varicella zoster virus without eruption. Case Rep Med. 2014;2014:916265.PubMedPubMed CentralGoogle Scholar
- Powell KF, Wilson HG, Croxson MC, Marshall MR, Wong EH, Anderson NE, et al. Herpes zoster meningoencephalitis without rash: Varicella zoster virus DNA in CSF. J Neurol Neurosurg Psychiatry. 1995;59:198–9.PubMedPubMed CentralView ArticleGoogle Scholar
- Chen MJ, Chen KH, Chung YM, Li AF, Chou CK, Hsu WM. Detection of varicella-zoster virus DNA in the iris of a zoster sine herpete patient. Int J Biomed Sci. 2006;2:302–4.PubMedPubMed CentralGoogle Scholar
- Lo CH, Chiang CP. Herpes zoster duplex bilateralis. Intern Med. 2013;52:2841.PubMedView ArticleGoogle Scholar
- Shin JW, Kim DH, Whang KU, Lee J, Park Y, Cho MK, et al. A case of zoster duplex bilateralis. Ann Dermatol. 2009;21:423–5.PubMedPubMed CentralView ArticleGoogle Scholar
- Mabuchi T, Yamaoka H, Kato M, Ikoma N, Tamiya S, Song HJ, et al. Case of disseminated vesicles of herpes zoster developing one day before the onset of local eruption in a hospitalized immunocompromised patient. Tokai J Exp Clin Med. 2013;38:52–4.PubMedGoogle Scholar
- Kim H, Kang JN, Seol JE, Seo JK, Sung HS. Epidemiology and clinical features of disseminated herpes zoster. Korean J Dermatol. 2013;51:507–12.Google Scholar
- Qi X-L, Li C-X, Gao T-W. Herpes zoster generalisatus caused by long-term treatment of cyclosporin: A case report. J Clin Dermatol. 2006;35:313–14.Google Scholar
- Park S-H, Lee SY, Yi JH, Choi HS, Yun SK, Kim HU, Ihm CW. A case of herpes zoster duplex unilateralis with herpes zoster generalisatus. Korean J Dermatol. 2005;43:1579–81.Google Scholar
- Takaoka Y, Miyachi Y, Yoshikawa Y, Tanioka M, Fujisawa A, Endo Y. Bilateral disseminated herpes zoster in an immunocompetent host. Dermatol Online J. 2013;19:13.PubMedGoogle Scholar
- Gupta LK, Kuldeep CM, Mittal A, Singhal H. Multidermatomal herpes zoster in an immunocompetent female. Indian J Dermatol Venereol Leprol. 2005;71:210–11.PubMedView ArticleGoogle Scholar
- Sun ZH, Guo YY, Li M, Yao ZR. Disseminated herpes zoster in immunocompetent patients not due to varicella-zoster virus gene mutation. Chin Med J. 2013;126:3193.PubMedGoogle Scholar
- Mittal RR. Disseminated herpes zoster. Indian J Dermatol Venereol Leprol. 1995;61:148–9.PubMedGoogle Scholar
- Gahalaut P, Chauhan S. Herpes zoster duplex bilateralis in an immunocompetent host. Indian Dermatol Online J. 2012;3:31–3.PubMedPubMed CentralView ArticleGoogle Scholar
- Lee H, Jung HJ, Park MY, Ann JY. Herpes zoster duplex symmetricus in a healthy patient. Korean J Dermatol. 2011;49:1098–101.Google Scholar
- Tsai YC, Tsai TF. Herpes zoster duplex bilateralis symmetricus. Dermatol Sin. 2015;33:37–8.View ArticleGoogle Scholar
- Yoon KJ, Kim SH, Lee EH, Choi JH. Disseminated herpes zoster in an immunocompetent elderly patient. Korean J Pain. 2013;26:195–8.PubMedPubMed CentralView ArticleGoogle Scholar
- Brar BK, Gupta RR, Saghni SS. Bilateral herpes - zoster of widely separated dermatomes in a non-immunocompromised female. Indian J Dermatol Venereol Leprol. 2002;68:48–9.PubMedGoogle Scholar
- Agrawal S, Aara N, Bumb R. Herpes zoster duplex bilateralis symmetricus in an immunocompetent subject. Int J Dermatol. 2014;53:e281–2.PubMedView ArticleGoogle Scholar
- Oh KH, Ahn C, Kim YS, Han JS, Kim S, Lee JS, et al. Atypical generalized zoster with suspicious esophageal involvement and early relapse in an adult renal transplant recepient. Transplant Proc. 2002;34:1174–7.PubMedView ArticleGoogle Scholar
- Tan HH, Goh CL. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol. 2006;7:13–29.PubMedView ArticleGoogle Scholar
- Kui YP, Hye IL, Ji YK, Kap SL, Seong JS, Chang KH. A case of herpes zoster multiplex in five disparate dermatomes. Korean J Dermatol. 2008;46:973–6.Google Scholar
- Yoo KH, Park JH, Kim BJ, Kim MN, Song KY. Herpes zoster duplex bilateralis in a patient with breast cancer. Cancer Res Treat. 2009;41:50–2.PubMedPubMed CentralView ArticleGoogle Scholar
- Ko DH, Park SY, Yoon TJ. A case of bilateral recurrent herpes zoster in multiple myeloma. Korean J Dermatol. 2006;44:1460–3.Google Scholar
- Teranishi H, Sakiyama M, Nagatoshi Y, Nomura Y, Inagaki J, Yanai F, et al. Acute lymphoblastic leukemia complicated with varicella zoster virus meningoencephalitis and visceral dissemination after related bone marrow transplantation. Rinsho Ketsueki. 2011;52:287–92.PubMedGoogle Scholar
- Endoh K, Kawai N, Itoh K, Tominaga K, Kusumoto S, Fukuda M, et al. An autopsy case of non-Hodgkin's lymphoma complicated by fulminant infiltration by disseminated herpes zoster. Jpn J Chemother. 2000;48:75–8.Google Scholar
- Ryu DJ, Jung JY, Lee S, Lee JH. A case of herpes zoster duplex bilateralis, a diagnostic clue of human immunodeficiency virus infection. Korean J Dermatol. 2010;48:339–41.Google Scholar
- Rajashekar TS, Singh G, Shivakumar V, Okade R. Recurrent herpes zoster duplex symmetricus in HIV infection. Indian J Dermatol. 2008;53:33–4.PubMedPubMed CentralView ArticleGoogle Scholar
- Sundriyal D, Kapoor R, Kumar N, Walia M. Multidermatomal herpes zoster. BMJ Case Rep. 2014. doi:10.1136/bcr-2014-205024.Google Scholar
- Zhang B, Zhao HX, Lun WH, Sun N, Yang D, Liang HY, et al. Generalized varicella-zoster virus infection: A case report. J Clin Dermatol. 2013;42:595–7.Google Scholar
- Chacko S, John TJ, Babu PG, Jacob M, Kaur A, Mathai D. Clinical profile of AIDS in India: a review of 61 cases. J Assoc Physicians India. 1995;43:535–8.PubMedGoogle Scholar
- Higashitake I, Higaki T, Souda N, Yamada H. Recurrent herpes zoster seen in the patient of human immunodeficiency virus infection. Skin Res. 2004;3:216–9.Google Scholar
- Kar HK, Gautam RK, Jain RK, Puri P, Doda V. Disseminated cutaneous herpes zoster: A clinical predictor of human immunodeficiency virus infection. Indian J Dermatol Venereol Leprol. 1995;61:40–1.PubMedGoogle Scholar
- Shin BS, Na CH, Song IG, Choi KC. A case of human immunodeficiency virus infection initially presented with disseminated herpes zoster. Ann Dermatol. 2010;22:199–202.PubMedPubMed CentralView ArticleGoogle Scholar
- Kim WJ, Park JW, Shin DH, Choi JS, Kim KH. A case of human immunodeficiency virus infection in recurrent herpes zoster. Korean J Dermatol. 2005;43:271–3.Google Scholar
- Kim MS, Choi H, Na CH, Shin BS. A 5-year period clinical study of 16 cases with disseminated herpes zoster (2008–2012). Korean J Dermatol. 2013;51:322–8.Google Scholar
- Doki N, Miyawaki S, Tanaka M, Kudo D, Wake A, Oshima K, et al. Visceral varicella zoster virus infection after allogeneic stem cell transplantation. Transpl Infect Dis. 2013;15:314–8.PubMedView ArticleGoogle Scholar
- Saitoh H, Takahashi N, Nanjo H, Kawabata Y, Hirokawa M, Sawada K. Varicella-zoster virus-associated fulminant hepatitis following allogeneic hematopoietic stem cell transplantation for multiple myeloma. Intern Med. 2013;52:1727–30.PubMedView ArticleGoogle Scholar
- Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant. 2006;20:485–9.PubMedView ArticleGoogle Scholar
- Ohara F, Kobayashi Y, Akabane D, Maruyama D, Tanimoto K, Kim SW, et al. Abdominal pain and syndrome of inappropriate antidiuretic hormone secretion as a manifestation of visceral varicella zoster virus infection in a patient with non-Hodgkin's lymphoma. Am J Hematol. 2007;82:416.PubMedView ArticleGoogle Scholar
- Yakushijin Y, Minamoto Y, Takada K, Otsuka M, Yasukawa M, Fujita S. A case of fatal varicella zoster infection with refractory abdominal pain as an early symptom. Kansenshogaku Zasshi. 2004;78:64–9.PubMedView ArticleGoogle Scholar
- Au WY, Ma SY, Cheng VC, Ooi CG, Lie AK. Disseminated zoster, hyponatraemia, severe abdominal pain and leukaemia relapse: recognition of a new clinical quartet after bone marrow transplantation. Br J Dermatol. 2003;149:862–5.PubMedView ArticleGoogle Scholar
- Kurtovic J, Webster GJM, Singh-Grewal I, Bullpitt P, Haindl W, Wakefield D, et al. Acalculous cholecystitis, multifocal gastrointestinal infarction and pancreatitis resulting from Varicella-zoster virus. Intern Med J. 2005;35:69–70.PubMedView ArticleGoogle Scholar
- Wang Z, Ye J, Han YH. Acute pancreatitis associated with herpes zoster: Case report and literature review. World J Gastroenterol. 2014;20:18053–6.PubMedPubMed CentralGoogle Scholar
- Okimura H, Muto M, Ichimiya M, Mogami S, Takahata H, Asagami C. A case of herpes zoster associated with colitis. J Dermatol. 1996;23:631–4.PubMedView ArticleGoogle Scholar
- Ching DW. Severe, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1995;54:155.PubMedPubMed CentralView ArticleGoogle Scholar
- Hashizume H, Umayahara T. Acute respiratory distress syndrome due to varicella zoster virus pneumonitis in an immunocompromised patient with herpes zoster. J Dermatol. 2013;40:1064–5.PubMedView ArticleGoogle Scholar
- Nakamura M, Kanazawa M, Yamaguchi K, Akizuki M, Satoh S, Inada S. Pneumonia caused by varicella-zoster virus in a patient with rheumatoid arthritis. Nihon Kyobu Shikkan Gakkai Zasshi. 1996;34:610–5.PubMedGoogle Scholar
- Miyazaki T, Tanabe Y, Iseki M. Treatment and recent topics of postherpetic neuralgia. Japan Med Assoc J. 2005;48:505–10.Google Scholar
- Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27:159–76.PubMedView ArticleGoogle Scholar
- Cheong C, Lee TJ. Prevalence and healthcare utilization of herpes zoster and postherpetic neuralgia in South Korea: disparity among patients with different immune statuses. Epidemiol Health. 2014;36:e2014012.PubMedPubMed CentralView ArticleGoogle Scholar
- Higa K, Mori M, Hirata K, Hori K, Manabe H, Dan K. Severity of skin lesions of herpes zoster at the worst phase rather than age and involved region most influences the duration of acute herpetic pain. Pain. 1997;69:245–53.PubMedView ArticleGoogle Scholar
- Sagong C, Yeo KY, Kim JS, Yu HJ, Kim DH. The relationship among pain, depression, and anxiety in patients with herpes zoster. Korean J Dermatol. 2009;47:403–10.Google Scholar
- Decroix J, Partsch H, Gonzalez R, Mobacken H, Goh CL, Walsh JB, et al. Factors influencing pain outcome in herpes zoster: An observational study with valaciclovir. J Eur Acad Dermatol Venereol. 2000;14:23–33.PubMedView ArticleGoogle Scholar
- Noh TW, Park HJ, Kim SH, Kang YS, Lee UH, Park HS. A clinical study of herpes zoster focused on the characteristics of pruritus in herpes zoster. Korean J Dermatol. 2012;50:591–8.Google Scholar
- Chant KG, Sullivan EA, Burgess MA, Ferson MJ, Forrest JM, Baird LM, et al. Varicella-zoster virus infection in Australia. Aust N Z J Public Health. 1998;22:413–8.PubMedView ArticleGoogle Scholar
- MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect. 2003;131:675–82.PubMedPubMed CentralView ArticleGoogle Scholar
- Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health. 1998;3:886–90.PubMedView ArticleGoogle Scholar
- Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine. 2009;27:520–9.PubMedView ArticleGoogle Scholar
- Dashraath P, Ong ES, Lee VJ. Seroepidemiology of varicella and the reliability of a self-reported history of varicella infection in Singapore military recruits. Ann Acad Med Singapore. 2007;36:636–41.PubMedGoogle Scholar
- Chow VTK. Rapid detection of varicella-zoster viral antibodies by latex agglutination assay: A practical experience for medical and science undergraduates. Biochem Educ. 1998;26:248–51.View ArticleGoogle Scholar
- Fatha N, Ang LW, Goh KT. Changing seroprevalence of varicella zoster virus infection in a tropical city state, Singapore. Int J Infect Dis. 2014;22:73–7.PubMedView ArticleGoogle Scholar
- Juffrie M, Graham RR, Tan RI, Widjaja S, Mulyadi S, Weil J, et al. Seroprevalence of hepatitis A virus and varicella zoster antibodies in a Javanese community (Yogyakarta, Indonesia). Southeast Asian J Trop Med Public Health. 2000;31:21–4.PubMedGoogle Scholar
- Sam IC, Tariman H, Chan YF, Bador MK, Yusof MY, Hassan H. Varicella-zoster virus seroprevalence in healthcare workers in Kuala Lumpur, Malaysia. Med J Malaysia. 2008;63:429–30.PubMedGoogle Scholar
- Barzaga NG, Roxas JR, Florese RH. Varicella zoster virus prevalence in Metro Manila, Philippines. J Am Med Assoc (SE Asia). 1994;274(Suppl):S633–35.Google Scholar
- Lokeshwar MR, Agrawal A, Subbarao SD, Chakraborty MS, Ram Prasad AV, Weil J, et al. Age related seroprevalence of antibodies to varicella in India. Indian Pediatr. 2000;37:714–9.PubMedGoogle Scholar
- Migasena S, Simasathien S, Desakorn V, Phonrat B, Suntharasamai P, Pitisuttitham P, et al. Seroprevalence of varicella-zoster virus antibody in Thailand. Int J Infect Dis. 1997;2:26–30.View ArticleGoogle Scholar
- Bhattarakosol P, Chantarabul S, Pittayathikhun K, Mung-mee V, Punnarugsa V. Prevalence of anti-varicella zoster IgG antibody in undergraduate students. Asian Pac J Allergy Immunol. 1996;14:129–31.PubMedGoogle Scholar
- Lolekha S, Tanthiphabha W, Sornchai P, Kosuwan P, Sutra S, Warachit B, et al. Effect of climatic factors and population density on varicella zoster virus epidemiology within a tropical country. Am J Trop Med Hyg. 2001;64:131–6.PubMedGoogle Scholar
- Srichomkwun P, Apisarnthanarak A, Thongphubeth K, Yuekyen C, Mundy LM. Evidence of vaccine protection among Thai medical students and implications for occupational health. Infect Control Hosp Epidemiol. 2009;30:585–8.PubMedView ArticleGoogle Scholar
- Suwanpakdee D, Laohapand C, Moolasart V, Lomtong P, Krairojananan N, Srisawat P, et al. Serosurveillance of varicella and hepatitis B infection after reported cases in medical students and the relationship between past varicella disease history and immunity status. J Med Assoc Thai. 2012;95 Suppl 5:S80–5.PubMedGoogle Scholar
- Kowitdamrong E, Pancharoen C, Thammaborvorn R, Bhattarakosol P. The prevalence of varicella-zoster virus infection in normal healthy individuals aged above 6 months. J Med Assoc Thai. 2005;88 Suppl 4:S7–11.PubMedGoogle Scholar
- O'Grady KA, Merianos A, Patel M, Gilbert L. High seroprevalence of antibodies to varicella zoster virus in adult women in a tropical climate. Trop Med Int Health. 2000;5:732–6.PubMedView ArticleGoogle Scholar
- Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL. The seroepidemiology and transmission dynamics of varicella in Australia. Epidemiol Infect. 2003;131:1085–9.PubMedPubMed CentralView ArticleGoogle Scholar
- Lin YJ, Huang LM, Lee CY, Chih TW, Lee PL, Chang LY, et al. A seroepidemiological study of Varicella-Zoster virus in Taipei City. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1996;37:11–5.PubMedGoogle Scholar
- Wu MF, Yang YW, Lin WY, Chang CY, Soon MS, Liu CE. Varicella zoster virus infection among healthcare workers in Taiwan: seroprevalence and predictive value of history of varicella infection. J Hosp Infect. 2012;80:162–7.PubMedView ArticleGoogle Scholar
- Kangro HO, Osman HK, Lau YL, Heath RB, Yeung CY, Ng MH. Seroprevalence of antibodies to human herpesviruses in England and Hong Kong. J Med Virol. 1994;43:91–6.PubMedView ArticleGoogle Scholar
- Fung LW, Lao TT, Suen SS, Chan OK, Lau TK, Ngai KL, et al. Seroprevalence of varicella zoster virus among pregnant women in Hong Kong: comparison with self-reported history. Vaccine. 2011;29:8186–8.PubMedView ArticleGoogle Scholar
- Liu JJ, Wang ML, Gan L, Liao WJ, Chen J. Seroepidemiology of varicella-zoster virus infection measured by the fluorescent antibody to membrane antigen test. Zhonghua Liu Xing Bing Xue Za Zhi. 2009;30:371–5.PubMedGoogle Scholar
- Zhou Z, Wang S, Chu Y, Xie G. Survey of seroprevalence of varicella zoster virus in healthy population in Shanghai. Chin J Vaccin Immun. 2006;2:137–9.Google Scholar
- Wang Y. Seroepidemiological survey of prevalence of varicella-zoster virus in healthy population in Shenzen City. Chin Trop Med. 2006;7:1166–7.Google Scholar
- Pan W, Zhang X, Cai Z, Zhang H. A sero-epidemiological investigation on varicella-zoster virus in healthy people in Fujian. Pract Prev Med. 2003;6:864–5.Google Scholar
- Han SB, Kang KR, Huh DH, Lee HC, Kim JH, Kang JH, et al. Seroepidemiology of varicella-zoster virus in Korean adolescents and adults using fluorescent antibody to membrane antigen test. Epidemiol Infect. 2015;143:1643–50.PubMedView ArticleGoogle Scholar
- Kang CI, Choi CM, Park TS, Lee DJ, Oh MD, Choe KW. Incidence of herpes zoster and seroprevalence of varicella-zoster virus in young adults of South Korea. Int J Infect Dis. 2008;12:245–7.PubMedView ArticleGoogle Scholar
- Choi YJ, Kim KH, Oh MD. Genotype of varicella zoster virus isolated from Korean elderly patients with herpes zoster. Infect Chemother. 2010;42:162–70.View ArticleGoogle Scholar
- Lee H, Cho HK, Kim KH. Seroepidemiology of varicella-zoster virus in Korea. J Korean Med Sci. 2013;28:195–9.PubMedPubMed CentralView ArticleGoogle Scholar
- Kang JH, Park YS, Park SY, Kim SB, Ko KP, Seo YH. Varicella seroprevalence among health care workers in Korea: validity of self-reported history and cost-effectiveness of prevaccination screening. Am J Infect Control. 2014;42:885–7.PubMedView ArticleGoogle Scholar
- Kim YH, Hwang JY, Lee KM, Choi JH, Lee TY, Choi JS, et al. Seroepidemiologic survey of varicella-zoster virus in Korean adults using glycoprotein enzyme immuno assay and fluorescent antibody to membrane antigen test. Ann Dermatol. 2011;23:39–43.PubMedPubMed CentralView ArticleGoogle Scholar
- Yoshida N, Tsumura N, Toyomasu K, Sagawa K. Antibody titers against measles, rubella, mumps and varicella-zoster viruses in medical students. Sangyo Eiseigaku Zasshi. 2007;49:21–6.PubMedView ArticleGoogle Scholar
- National Institute of Infectious Diseases, Japan. National Epidemiological Surveillance of Vaccine-Preventable Diseases, 2015. Age distribution of varicella EIA-IgG antibody positives in Japan, 2015. http://www.nih.go.jp/niid/ja/y-graphs/6358-varicella-yosoku-serum2015.html. Accessed 27 Sept 2016.
- Lin YH, Huang LM, Chang IS, Tsai FY, Lu CY, Shao PL, et al. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010;28:1217–20.PubMedView ArticleGoogle Scholar
- Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol. 2009;89:612–6.PubMedView ArticleGoogle Scholar
- Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the epidemiology of herpes zoster in Korea. J Korean Med Sci. 2014;29:1706–10.PubMedPubMed CentralView ArticleGoogle Scholar
- Toyama N, Shiraki K. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol. 2009;81:2053–8.PubMedView ArticleGoogle Scholar
- Choi WS, Noh JY, Huh JY, Jo YM, Lee J, Song JY, et al. Disease burden of herpes zoster in Korea. J Clin Virol. 2010;47:325–9.PubMedView ArticleGoogle Scholar
- Wu PY, Wu HD, Chou TC, Sung FC. Varicella vaccination alters the chronological trends of herpes zoster and varicella. PLoS One. 2013;8:e77709.PubMedPubMed CentralView ArticleGoogle Scholar
- Wu CY, Hu HY, Huang N, Pu CY, Shen HC, Chou YJ. Do the health-care workers gain protection against herpes zoster infection? A 6-year population-based study in Taiwan. J Dermatol. 2010;37:463–70.PubMedView ArticleGoogle Scholar
- Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000–2008. Epidemiol Infect. 2012;140:1131–40.PubMedView ArticleGoogle Scholar
- Pongsumpun P. Local stability analysis of age structural model for herpes zoster in Thailand. Int J Math Comput Stat Nat Phys Eng. 2013;7:1146–52.Google Scholar
- Nelson MR, Britt HC, Harrison CM. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Med J Aust. 2010;193:110–3.PubMedGoogle Scholar
- Kelly HA, Grant KA, Gidding H, Carville KS. Decreased varicella and increased herpes zoster incidence at a sentinel medical deputising service in a setting of increasing varicella vaccine coverage in Victoria, Australia, 1998 to 2012. Euro Surveill. 2014;19(41):pii=20926. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20926.
- Carville KS, Riddell MA, Kelly HA. A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine. 2010;28:2532–8.PubMedView ArticleGoogle Scholar
- Bak H, Ahn SK. A statistical study of dermatoses (2000–2004). Korean J Dermatol. 2005;43:1192–9.Google Scholar
- Lee H-J, Choi SI, Ahn SK. A statistical study of dermatoses in Wonju (2005 ~ 2009). Korean J Dermatol. 2010;48:460–7.Google Scholar
- Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health, Thailand. Annual Epidemiological Surveillance Reports. 1993–2014. http://www.boe.moph.go.th/boedb/surdata/disease.php?dcontent=old&ds=77. Accessed 03 Aug 2015.
- Ogunjimi B, Van Damme P, Beutels P. Herpes zoster risk reduction through exposure to chickenpox patients: A systematic multidisciplinary review. PLoS One. 2013;8:e66485.
- Jardine A, Conaty SJ, Vally H. Herpes zoster in Australia: Evidence of increase in incidence in adults attributable to varicella immunization? Epidemiol Infect. 2011;139:658–65.PubMedView ArticleGoogle Scholar
- Jeong SK, Kim IH. Recurrence rate of herpes zoster during the previous decade. Korean J Dermatol. 2012;50:287–9.Google Scholar
- Tunsuriyawong S, Puavilai S. Herpes zoster, clinical course and associated diseases: A 5-year retrospective study at Ramathibodi Hospital. J Med Assoc Thai. 2005;88:678–81.PubMedGoogle Scholar
- Ikeda M, Hiroshige K, Abiko Y, Onoda K. Impaired specific cellular immunity to the varicella-zoster virus in patients with herpes zoster oticus. J Laryngol Otol. 1996;110:918–21.PubMedView ArticleGoogle Scholar
- Tang H, Moriishi E, Okamoto S, Okuno Y, Iso H, Asada H, et al. A community-based survey of varicella-zoster virus-specific immune responses in the elderly. J Clin Virol. 2012;55:46–50.PubMedView ArticleGoogle Scholar
- Lin SY, Liu JH, Lin CL, Tsai IJ, Chen PC, Chung CJ, et al. A comparison of herpes zoster incidence across the spectrum of chronic kidney disease, dialysis and transplantation. Am J Nephrol. 2012;36:27–33.PubMedView ArticleGoogle Scholar
- Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39:537–44.PubMedPubMed CentralView ArticleGoogle Scholar
- Kuo CC, Lee CT, Lee IM, Ho SC, Yang CY. Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study. Am J Kidney Dis. 2012;59:428–33.PubMedView ArticleGoogle Scholar
- Wu MY, Hsu YH, Su CL, Lin YF, Lin HW. Risk of herpes zoster in CKD: a matched-cohort study based on administrative data. Am J Kidney Dis. 2012;60:548–52.PubMedView ArticleGoogle Scholar
- Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo). 2011;66:1177–82.View ArticleGoogle Scholar
- Tsai SY, Yang TY, Lin CL, Tsai YH, Kuo CF, Kao CH. Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study. Int J Clin Pract. 2015;69:228–34.PubMedView ArticleGoogle Scholar
- Chen JY, Cheng TJ, Chang CY, Lan KM, Weng SF, Sheu MJ, et al. Increased incidence of herpes zoster in adult patients with peptic ulcer disease: A population-based cohort study. Int J Epidemiol. 2013;42:1873–81.PubMedView ArticleGoogle Scholar
- Yang YW, Chen YH, Wang KH, Wang CY, Lin HW. Risk of herpes zoster among patients with chronic obstructive pulmonary disease: a population-based study. CMAJ. 2011;183:E275–80.PubMedPubMed CentralView ArticleGoogle Scholar
- Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Risk of herpes zoster in psoriatic patients undergoing biologic treatment. J Dermatol. 2014;41:168–70.PubMedView ArticleGoogle Scholar
- Hu SC, Lin CL, Lu YW, Chen GS, Yu HS, Wu CS, et al. Lymphopaenia, anti-Ro/anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus. Acta Derm Venereol. 2013;93:314–8.PubMedView ArticleGoogle Scholar
- Zou Y, Lin M, Sheng Z, Niu S. Bortezomib and lenalidomide as front-line therapy for multiple myeloma. Leuk Lymphoma. 2014;55:2024–31.PubMedView ArticleGoogle Scholar
- Lyu SM, Byun JY, Choi YW, Choi HY. Clinical features of dermatology-consulted inpatients - Focus on the differences between individual departments. Korean J Dermatol. 2014;52:215–21.Google Scholar
- Oh SI, Oh BH, Rho JR, Kim KB, Kim JJ, Song MG, et al. Results of heart transplantation in Korea. Korean J Med. 2001;60:228–33.Google Scholar
- Tzeng CH, Liu JH, Fan S, Wang SY, Wang SR, Chen KY, et al. Varicella zoster virus infection after allogeneic or autologous hemopoietic stem cell transplantation. J Formos Med Assoc. 1995;94:313–7.PubMedGoogle Scholar
- Nakasone H, Izutsu K, Wakita S, Yamaguchi H, Muramatsu-Kida M, Usuki K. Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. Biol Blood Marrow Transplant. 2008;14:1262–9.PubMedView ArticleGoogle Scholar
- Tsukamoto H, Nagafuji K, Horiuchi T, Miyamoto T, Aoki K, Takase K, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis. 2006;65:508–14.PubMedView ArticleGoogle Scholar
- Jiang Z, Xiao H, Pang Y, Xiao Y. The incidence of herpes zoster after hematopoietic stem cell transplantation. Chin J Infect Chemother. 2012;12:88–91.Google Scholar
- Chugh KS, Sharma SC, Singh V, Sakhuja V, Jha V, Gupta KL. Spectrum of dermatological lesions in renal allograft recipients in a tropical environment. Dermatology. 1994;188:108–12.PubMedView ArticleGoogle Scholar
- Prakash J, Singh S, Prashant GK, Kar B, Tripathi K, Singh PB. Mucocutaneous lesions in transplant recipient in a tropical country. Transplant Proc. 2004;36:2162–4.PubMedView ArticleGoogle Scholar
- Hwang EA, Kang MJ, Han SY, Park SB, Kim HC. Viral infection following kidney transplantation: long-term follow-up in a single center. Transplant Proc. 2004;36:2118–9.PubMedView ArticleGoogle Scholar
- Ko GB, Kim T, Kim SH, Choi SH, Kim YS, Woo JH, et al. Increased incidence of herpes zoster in the setting of cytomegalovirus preemptive therapy after kidney transplantation. Transpl Infect Dis. 2013;15:416–23.PubMedView ArticleGoogle Scholar
- Vinod PB, Sharma RK. Opportunistic infections (non-cytomegalovirus) in live related renal transplant recipients. Indian J Urol. 2009;25:161–8.PubMedPubMed CentralView ArticleGoogle Scholar
- Ng P, McCluskey P, McCaughan G, Glanville A, MacDonald P, Keogh A. Ocular complications of heart, lung, and liver transplantation. Br J Ophthalmol. 1998;82:423–8.PubMedPubMed CentralView ArticleGoogle Scholar
- Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol. 2004;15:809–17.PubMedView ArticleGoogle Scholar
- Tomonari A, Iseki T, Takahashi S, Ooi J, Takasugi K, Shimohakamada Y, et al. Varicella-zoster virus infection in adult patients after unrelated cord blood transplantation: a single institute experience in Japan. Br J Haematol. 2003;122:802–5.PubMedView ArticleGoogle Scholar
- Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T, et al. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group. Biol Blood Marrow Transplant. 2009;15:724–9.PubMedView ArticleGoogle Scholar
- Wu M, Huang F, Jiang X, Fan Z, Zhou H, Liu C, et al. Herpesvirus-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation. PLoS One. 2013;8:e77805.PubMedPubMed CentralView ArticleGoogle Scholar
- Suzuki J, Ashizawa M, Okuda S, Wada H, Sakamoto K, Terasako K, et al. Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2012;14:E7–12.PubMedView ArticleGoogle Scholar
- Au WY, Hon C, Cheng VCC, Ma ESK. Concomitant zoster myelitis and cerebral leukemia relapse after stem cell transplantation. Ann Hematol. 2005;84:59–60.PubMedView ArticleGoogle Scholar
- Fukuno K, Tomonari A, Takahashi S, Ooi J, Takasugi K, Tsukada N, et al. Varicella-zoster virus encephalitis in a patient undergoing unrelated cord blood transplantation for myelodysplastic syndrome-overt leukemia. Int J Hematol. 2006;84:79–82.PubMedView ArticleGoogle Scholar
- Kang EH, Chung MP, Kang SJ, An CH, Ahn JW, Han J, Lee. Clinical features and treatment response in 18 cases with idiopathic nonspecific interstitial pneumonia. Tuberc Respir Dis. 2000;48:530–41.View ArticleGoogle Scholar
- Ozono Y, Harada T, Yamaguchi K, Taura K, Hara K, Taguchi T. Nephrotic syndrome in the elderly–clinicopathological study. Nihon Jinzo Gakkai Shi. 1994;36:44–50.PubMedGoogle Scholar
- Satoh N, Abe T, Nakajima A, Sakuragi S. Recurrent varicella-zoster virus retinitis in a patient treated with systemic corticosteroids. Ocul Immunol Inflamm. 1998;6:185–8.PubMedView ArticleGoogle Scholar
- Xiao X, Lu Y, Su H, Zhong K, Chen X, Da Y, et al. Clinical features and treatment of angioimmunoblastic T-cell lymphoma. Chin J Clin Oncol. 2011;38:1103–6.Google Scholar
- Usami E, Kimura M, Matsuoka T, Okada K, Nakao T, Yoshimura T, et al. The frequency and risk factor of herpes zoster infection in non-Hodgkin's lymphoma patients. Jpn J Cancer Chemother. 2011;38:243–7.Google Scholar
- Mills AK, Taylor KM, Wright SJ, Bunce LH, Bashford J, White K, et al. Sustained responses following alternating chlorodeoxyadenosine (2CDA) and VAC regimen in poor-risk de-novo follicular non-hodgkin's lymphoma (NHL). In: Blood 2000;96(11) Part II: The 2nd Annual Scientific Meeting of the Haematology Society of Australia and New Zealand, Perth, WA, 25–28 July 2000. p. 243b.
- Au WY, Kwong YL. Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge. J Am Acad Dermatol. 2005;53:890–2.PubMedView ArticleGoogle Scholar
- Zhang Q, Mu LJ, Wang XB, Li L, Kang ZJ, Yan JS. Clinical analysis of hematologic disorders complicated with herpes zoster after treating with arsenic trioxide. J Leuk Lymphoma. 2011;20:412–4.Google Scholar
- Yamakura M, Tsuda K, Ugai T, Sugihara H, Nisihida Y, Takeuchi M, et al. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia. Acta Haematol. 2014;131:76–7.PubMedView ArticleGoogle Scholar
- Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood. 2011;118:6535–43.PubMedView ArticleGoogle Scholar
- Chan AYK, Hooi LS. Outcome of 85 lupus nephritis patients treated with intravenous clophosphamide: A single centre 10 year experience. Med J Malays. 2000;55:14–20.Google Scholar
- Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK. Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron. 1995;71:321–7.PubMedView ArticleGoogle Scholar
- Chan TM, Li FK, Hao WK, Chan KW, Lui SL, Tang S, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus. 1999;8:545–51.PubMedView ArticleGoogle Scholar
- Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis. 2001;38:256–64.PubMedView ArticleGoogle Scholar
- Liu G, Chen Y, Zuo C, Xie Q, Wang Z, Wang L, et al. Study on bolus cyclosphamide treatment for 64 cases of lupus nephritis. J West China Univ Med Sci. 2001;32:129–130,139.Google Scholar
- Mok CC, Ying KY, Mak A, To CH, Szeto ML. Outcome of protein-losing gastroenteropathy in systemic lupus erythematosus treated with prednisolone and azathioprine. Rheumatology (Oxford). 2006;45:425–9.View ArticleGoogle Scholar
- Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J Gastroenterol. 2008;51:291–7.PubMedGoogle Scholar
- Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24:517–25.PubMedView ArticleGoogle Scholar
- Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20:1484–93.PubMedView ArticleGoogle Scholar
- Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant. 2008;23:1307–12.PubMedView ArticleGoogle Scholar
- Kim YS, Moon JI, Kim SI, Park K. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. Transplantation. 1999;68:578–81.PubMedView ArticleGoogle Scholar
- Lu F, Tu Y, Peng X, Wang L, Wang H, Sun Z, et al. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus. 2008;17:622–9.View ArticleGoogle Scholar
- Hegde S, Annamalai R, Biswas J. Extensive herpes zoster involvement following mycophenolate mofetil therapy for sarcoidosis. J Ophthalmic Inflamm Infect. 2012;2:47–8.PubMedView ArticleGoogle Scholar
- Satoh S, Tada H, Murakami M, Tsuchiya N, Inoue T, Togashi H, et al. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation. Transplant Proc. 2005;37:1751–3.PubMedView ArticleGoogle Scholar
- Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton). 2012;17:352–7.View ArticleGoogle Scholar
- Mak SK, Lo KY, Lo MW, Chan SF, Tong GM, Wong PN, et al. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis. Nephrology (Carlton). 2008;13:331–6.View ArticleGoogle Scholar
- Li L, Wang H, Lin S, et al. Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China. Zhonghua Nei Ke Za Zhi. 2002;41:476–9.PubMedGoogle Scholar
- Xie QX, Han CX, Li JY, Lin XC, Zhao L, Huang HW, et al. Application of low-dosage mycophenolate mofetil in living renal transplantation of lineal consanguinity. J Clin Rehab Tissue Eng Res. 2009;13:924–6.Google Scholar
- Jenks KA, Stamp LK, O'Donnell JL, Savage RL, Chapman PT. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34:2201–3.PubMedGoogle Scholar
- Yoo HG, Yu HM, Jun JB, Jeon HS, Yoo WH. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. Mod Rheumatol. 2013;23:709–15.PubMedView ArticleGoogle Scholar
- Cui TG, Hou FF, Ni ZH, Chen XM, Zhang FS, Zhu TY, et al. Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial. Zhonghua Nei Ke Za Zhi. 2005;44:672–6.PubMedGoogle Scholar
- Muir VJ, Plosker GL. Cladribine tablets: in relapsing-remitting multiple sclerosis. CNS Drugs. 2011;25:239–49.PubMedView ArticleGoogle Scholar
- Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, et al. Non-bacterial infections in Asian patients treated with alemtuzumab: A retrospective study of the Asian Lymphoma Study Group. Leuk Lymphoma. 2012;53:1515–24.PubMedView ArticleGoogle Scholar
- Chung BH, Kim Y, Jeong HS, Hong YA, Choi BS, Park CW, et al. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy. Transpl Immunol. 2014;31:140–4.PubMedView ArticleGoogle Scholar
- Ito K, Okamoto M, Maruyama F, Handa K, Yamamoto Y, Watanabe M, et al. Alteration in antibody-mediated immunity in patients with rituximab-combined chemotherapy and incidence of herpes zoster. Gan To Kagaku Ryoho. 2010;37:99–102.PubMedGoogle Scholar
- Kurokawa T, Hase M, Tokuman N, Yoshida T. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab. Hematol Oncol. 2011;29:5–9.PubMedView ArticleGoogle Scholar
- Lee SD, Kim SH, Kong SY, Kim YK, Lee SA, Park SJ. ABO-incompatible living donor liver transplantation without graft local infusion and splenectomy. HPB (Oxford). 2014;16:807–13.View ArticleGoogle Scholar
- Tu MF, Zheng W, Lin NJ, Zhang YT, Wang XP, Song YQ, et al. Efficacy and safety of fludarabine-based combination chemotherapy in patients with previously untreated follicular non-Hodgkin's lymphoma. Tumor. 2011;31:58–63.Google Scholar
- Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheum. 2014;66:379–89.View ArticleGoogle Scholar
- Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–86.PubMedView ArticleGoogle Scholar
- Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:2675–84.View ArticleGoogle Scholar
- Wang X, Zhao J, Zhu S, Xia B. Herpes zoster in Crohn's disease during treatment with infliximab. Eur J Gastroenterol Hepatol. 2014;26:237–9.PubMedView ArticleGoogle Scholar
- Choi KD, Song HJ, Kim JS, Jung HC, Song IS. Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea. Korean J Gastroenterol. 2005;46:48–55.PubMedGoogle Scholar
- Kim YJ, Kim JW, Lee CK, Park HJ, Shim JJ, Jang JY, et al. Clinical outcome of treatment with infliximab in Crohn's disease: a single-center experience. Korean J Gastroenterol. 2013;61:270–8.PubMedView ArticleGoogle Scholar
- Yi YS, Chung JS, Song MK, Shin HJ, Seol YM, Choi YJ, et al. The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma. Korean J Hematol. 2010;45:188–92.PubMedPubMed CentralView ArticleGoogle Scholar
- Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR, et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma. 2008;8:237–40.PubMedView ArticleGoogle Scholar
- Kim MG, Kim YJ, Kwon HY, Park HC, Koo TY, Jeong JC, et al. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Nephrology (Carlton). 2013;18:820–6.View ArticleGoogle Scholar
- Tong Y, Qian J, Li Y, Meng H, Jin J. The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol. 2007;82:403–4.PubMedView ArticleGoogle Scholar
- Zhong YP, Chen SL, Li X, Hu Y, Zhang JJ. Bortezomib combined with other drugs for treating 60 cases of multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17:214–7.PubMedGoogle Scholar
- Khalafallah AA, Woodgate M, Koshy K, Patrick A. Ophthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation. BMJ Case Rep. 2013; doi:10.1136/bcr-2012-007625.
- Zhang YQ, Liang R, Bai QX, Zhang T, Yang L, Wang YW, et al. PAD regimen for relapsed or refractory patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2009;30:260–3.PubMedGoogle Scholar
- Muta T, Nakanishi H, Yasunaga M, Senba S, Murakami H, Kan S, et al. Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure. Jpn J Cancer Chemother. 2011;38:237–41.Google Scholar
- Li CM, Lu H, Wu HX, Qiu HX, Qian SX, Xu W, et al. Therapeutic efficacy of bortezomib-based chemotherapy on 40 patients with multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18:1511–4.PubMedGoogle Scholar
- Yang G, Chen W, Wu Y. Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment. Chin J Cancer Res. 2013;25:155–60.PubMedPubMed CentralGoogle Scholar
- He J, Yang L, Han X, Zheng G, Zheng W, Wei G, et al. The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma. PLoS One. 2014;9:e99174.PubMedPubMed CentralView ArticleGoogle Scholar
- Huang B, Li J, Xu X, Zheng D, Zhou Z, Liu J. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD). Pathol Biol (Paris). 2015;63:17–20.View ArticleGoogle Scholar
- Zhang Y, Shi B, Chen X, Xia Y, Ye L, Liu L, et al. Bortezomib combined with doxorubicin and dexamethasone for patients with refractory senile mantle cell lymphoma. Chin J Clin Oncol. 2011;38:1092–4.Google Scholar
- Zhong YP, Chen SL. Effect of treatment by bortezomib with other drugs for the refractory multiple myeloma. J Leuk Lymphoma. 2009;18:538–40.Google Scholar
- Zhu JJ, Li L, Ye XJ, He JS, Cai Z. Bortezomib combined with epirubicin and dexamethasone in treatment of multiple myeloma. J Pract Oncol. 2013;28:520–2.Google Scholar
- Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, et al. A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression. Int J Hematol. 2009;89:342–7.PubMedView ArticleGoogle Scholar
- Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011;12:773–84.PubMedView ArticleGoogle Scholar
- Yang GZ, Chen WM, Shen M, Fu LN, Jiang L, Gao W, et al. Sequential therapy of BTD and MPT regimen for the newly-diagnosed multiple myeloma patients no eligible for bone marrow transplantation. J Leuk Lymphoma. 2011;20:350–2.Google Scholar
- Zhai YP, Liu HN, Yu YP, Zhou XG, Song P, Li F, et al. Treatment of primary systemic amyloidosis with the combination of bortezomib and dexamethasone. Zhonghua Xue Ye Xue Za Zhi. 2010;31:319–22.PubMedGoogle Scholar
- Gu HT, Shu MM, Gao GX, Dong BX, Liang R, Yang L, et al. Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. 2013;34:622–5.PubMedGoogle Scholar
- Zhao Y, Dou LP, Wang SH, Bo J, Wang QS, Huang WR, et al. The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma. Zhonghua Nei Ke Za Zhi. 2010;49:762–4.PubMedGoogle Scholar
- Hung MH, Kuo JR, Huang KF, Wang WC. Sacral herpes zoster presenting as sciatica. CMAJ. 2010;182:E534.PubMedPubMed CentralView ArticleGoogle Scholar
- Sachdeva S, Prasher P. Herpes zoster following saphenous venectomy for coronary bypass surgery. J Card Surg. 2010;25:28–9.PubMedView ArticleGoogle Scholar
- Basavaraj S, Prakash BG, Shetty TS, Sandhya D, Kallada S. Delayed facial nerve weakness after intact canal wall tympanomastoidectomy. Otol Neurotol. 2014;35:1003–6.PubMedView ArticleGoogle Scholar
- Lee MR, Ryman W. Herpes zoster following cryosurgery. Australas J Dermatol. 2005;46:42–3.PubMedView ArticleGoogle Scholar
- Brandon EL, Akers J, Rapeport D. Development of bilateral herpes zoster following thoracoscopic splanchnicectomy. Anaesth Intensive Care. 2006;34:382–3.PubMedGoogle Scholar
- Park KS, Yoon TR, Kim SK, Park HW, Song EK. Acute postoperative herpes zoster with a sciatic nerve distribution after total joint arthroplasty of the ipsilateral hip and contralateral knee. J Arthroplasty. 2010;25:497. e11-5.PubMedGoogle Scholar
- Choi HJ, Kim JH, Lee YM. Herpes zoster developing within recent subciliary incision scar. J Craniofac Surg. 2012;23:930–1.PubMedView ArticleGoogle Scholar
- Lin KC, Wang CC, Wang KY, Liao YC, Kuo JR. Reactivation of herpes zoster along the trigeminal nerve with intractable pain after facial trauma: a case report and literature review. BMJ Case Rep. 2009; doi:10.1136/bcr.07.2008.0525.
- Furuta Y, Ohtani F, Fukuda S, Inuyama Y, Nagashima K. Reactivation of varicella-zoster virus in delayed facial palsy after dental treatment and oro-facial surgery. J Med Virol. 2000;62:42–5.PubMedView ArticleGoogle Scholar
- Furukawa K, Sakoh M, Kumon Y, Teraoka M, Ohta S, Ohue S, et al. Delayed facial palsy after microvascular decompression for hemifacial spasm due to reactivation of varicella-zoster virus. No Shinkei Geka. 2003;31:899–902.PubMedGoogle Scholar
- Baba T, Yamasaki A, Miyake A, Funakoshi T, Yakura K, Miyazaki D, et al. Varicella zoster virus iridocyclitis following macular hole surgery in a case of von Hippel-Lindau disease. Jpn J Clin Ophthalmol. 2011;65:333–7.Google Scholar
- Fujitani A, Hayasaka S. Herpes zoster ophthalmicus after cataract surgery in a patient with a history of gastric cancer. Ann Ophthalmol Glaucoma. 1997;29:57–8.Google Scholar
- Koide C. Multiple cranial nerve dysfunction after uncomplicated neurovascular decompression for hemifacial spasm. Otolaryngol Head Neck Surg Tokyo. 1997;69:72–5.Google Scholar
- Tsukahara T, Huang J, Oyamada T, Uchio E. Herpetic corneal endotheliitis in a case after deep lamellar keratoplasty for bacterial keratitis. Jpn J Clin Ophthalmol. 2010;64:1287–91.Google Scholar
- Gyo K, Honda N. Delayed facial palsy after middle-ear surgery due to reactivation of varicella-zoster virus. J Laryngol Otol. 1999;113:914–5.PubMedView ArticleGoogle Scholar
- Kohjitani A, Miyawaki T, Kasuya K, Shimada M. Sympathetic activity-mediated neuropathic facial pain following simple tooth extraction: a case report. Cranio. 2002;20:135–8.PubMedView ArticleGoogle Scholar
- Walland MJ. Presumed ophthalmic Herpes zoster after contralateral cataract extraction. Acta Ophthalmol Scand. 1995;73:83–5.PubMedView ArticleGoogle Scholar
- Kam AC, Dan NG, Maclean J, Higgins D. Zoster related multiple cranial nerve palsies: an unusual complication following percutaneous balloon compression for trigeminal neuralgia. J Clin Neurosci. 1999;6:261–4.PubMedView ArticleGoogle Scholar
- Makkar JK, Singh NP, Rastogi V. Herpes zoster: Are selective nerve root injections the treatment or the cause? Pain Phys. 2010;13:196–8.Google Scholar
- Oh IH, Choi SK, Park BJ, Kim TS, Rhee BA, Lim YJ. The treatment outcome of elderly patients with idiopathic trigeminal neuralgia : Micro-vascular decompression versus gamma knife radiosurgery. J Korean Neurosurg Soc. 2008;44:199–204.PubMedPubMed CentralView ArticleGoogle Scholar
- Chen YH, Rau RH, Keller JJ, Lin HC. Possible effects of anaesthetic management on the 1 yr followed-up risk of herpes zoster after Caesarean deliveries. Br J Anaesth. 2012;108:278–82.PubMedView ArticleGoogle Scholar
- Terao M, Yamamoto T, Umeda J, Shirabe H. Drug induced herpes zoster (Do statin induce herpes zoster?). Skin Res. 2005;4:335–8.Google Scholar
- Chung SD, Tsai MC, Liu SP, Lin HC, Kang JH. Herpes zoster is associated with prior statin use: a population-based case–control study. PLoS One. 2014;9:e111268.PubMedPubMed CentralView ArticleGoogle Scholar
- Kano Y, Horie C, Inaoka M, Tadashi I, Mizukawa Y, Shiohara T. Herpes zoster in patients with drug-induced hypersensitivity syndrome/DRESS. Acta Derm-Venereol. 2012;92:206–7.PubMedView ArticleGoogle Scholar
- Follezou JY, Lan NY, Lien TX, Lafon ME, Tram LT, Hung PV, et al. Clinical and biological characteristics of human immunodeficiency virus- infected and uninfected intravascular drug users in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg. 1999;61:420–4.PubMedGoogle Scholar
- Sivayathorn A, Srihra B, Leesanguankul W. Prevalence of skin disease in patients infected with human immunodeficiency virus in Bangkok, Thailand. Ann Acad Med Singapore. 1995;24:528–33.PubMedGoogle Scholar
- Supanaranond W, Desakorn V, Sitakalin C, Naing N, Chirachankul P. Cutaneous manifestations in HIV positive patients. Southeast Asian J Trop Med Public Health. 2001;32:171–6.PubMedGoogle Scholar
- Li ZH, Hua YH. Clinical analysis of skin and mucosa manifestations in 130 patients with HIV. J Clin Dermatol. 2013;42:720–2.Google Scholar
- Wiwanitkit V. Prevalence of dermatological disorders in Thai HIV-infected patients correlated with different CD4 lymphocyte count statuses: a note on 120 cases. Int J Dermatol. 2004;43:265–8.PubMedView ArticleGoogle Scholar
- Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS. 2003;17:2129–31.PubMedView ArticleGoogle Scholar
- Tzung TY, Yang CY, Chao SC, Lee JY. Cutaneous manifestations of human immunodeficiency virus infection in Taiwan. Kaohsiung J Med Sci. 2004;20:216–24.PubMedView ArticleGoogle Scholar
- Dwiyana RF, Rowawi R, Lestari M, Alisjahbana B, van der Ven AJ, Djajakusumah TS. Skin disorders in HIV-infected patients from West Java. Acta Med Indones. 2009;41 Suppl 1:18–22.PubMedGoogle Scholar
- Wong KH, Lee SS, Lo YC, Li PC, Ho HF, Sitt WH, et al. Profile of opportunistic infections among HIV-1 infected people in Hong Kong. Zhonghua Yi Xue Za Zhi (Taipei). 1995;55:127–36.Google Scholar
- Huang XJ, Li HY, Chen DX, Wang XC, Li ZC, Wu YS, et al. Clinical analysis of skin lesions in 796 Chinese HIV- positive patients. Acta Derm Venereol. 2011;91:552–6.PubMedView ArticleGoogle Scholar
- Chen XC, Lu XJ, Ye H, Gao YY. Clinical analysis of 109 HIV/AIDS patients. Chin J Infect Chemother. 2008;8:183–6.Google Scholar
- Oh MD, Park SW, Kim HB, Kim US, Kim NJ, Choi HJ, et al. Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. Clin Infect Dis. 1999;29:1524–8.PubMedView ArticleGoogle Scholar
- Wani KA. Clinical profile of HIV/Aids patients in Srinagar, Kashmir, India. Int J Collab Res Intern Med Public Health. 2012;4:1703–12.Google Scholar
- Wadia RS, Pujari SN, Kothari S, Udhar M, Kulkarni S, Bhagat S, et al. Neurological Manifestations of HIV Disease. J Assoc Physicians India. 2001;49:343–8.PubMedGoogle Scholar
- Shobhana A, Guha SK, Neogi DK. Mucocutaneous manifestations of HIV infection. Indian J Dermatol Venereol Leprol. 2004;70:82–6.PubMedGoogle Scholar
- Arora U, Chopra S, Jindal N. HIV infection in families in and around Amritsar. J Indian Acad Clin Med. 2008;9:184–7.Google Scholar
- Ghate M, Deshpande S, Tripathy S, Nene M, Gedam P, Godbole S, et al. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis. 2009;13:e1–8.PubMedView ArticleGoogle Scholar
- Solomon SS, Hawcroft CS, Narasimhan P, Subbaraman R, Srikrishnan AK, Cecelia AJ, et al. Comorbidities among HIV-infected injection drug users in Chennai, India. Indian J Med Res. 2008;127:447–52.PubMedGoogle Scholar
- Jindal N, Aggarwal A, Kaur S. HIV seroprevalence and HIV associated dermatoses among patients presenting with skin and mucocutaneous disorders. Indian J Dermatol Venereol Leprol. 2009;75:283–6.PubMedView ArticleGoogle Scholar
- Kar HK, Narayan R, Gautam RK, Jain RK, Doda V, Sengupta D, et al. Mucocutaneous disorders in Hiv positive patients. Indian J Dermatol Venereol Leprol. 1996;62:283–5.PubMedGoogle Scholar
- Srirangaraj S, Venkatesha D. Opportunistic infections in relation to antiretroviral status among AIDS patients from south India. Indian J Med Microbiol. 2011;29:395–400.PubMedView ArticleGoogle Scholar
- Shahapur PR, Bidri RC. Recent trends in the spectrum of opportunistic infections in human immunodeficiency virus infected individuals on antiretroviral therapy in South India. J Nat Sci Biol Med. 2014;5:392–6.PubMedPubMed CentralView ArticleGoogle Scholar
- Song JY, Lee JS, Jung HW, Choi HJ, Lee JS, Eom JS, et al. Herpes zoster among HIV-infected patients in the highly active antiretroviral therapy era: Korean HIV cohort study. J Acquired Immune Defic Syndr. 2010;53:417–9.View ArticleGoogle Scholar
- Kim JM, Cho GJ, Hong SK, Chung JS, Jang KH, Kim CO, et al. Epidemiologic and clinical features of HIV infection/AIDS in Koreans. Korean J Med. 2001;61:355–64.View ArticleGoogle Scholar
- Nam TS, Seo KS, Lee KI, Kim YS, Hong JH, Kim GH, et al. The clinical study of hematoimmunologic features and opportunistic infections of patients with AIDS. Korean J Med. 1997;52:15–23.Google Scholar
- Choe KW, Oh MD, Park SW, Kim HB, Kim US, Kang SW, et al. Opportunistic infections and malignancies in 173 patients with HIV infection. Korean J Infect Dis. 1998;30:507–15.Google Scholar
- McNulty A, Li Y, Radtke U, Kaldor J, Rohrsheim R, Cooper DA, Donovan B. Herpes zoster and the stage and prognosis of HIV-1 infection. Genitourin Med. 1997;73:467–70.PubMedPubMed CentralGoogle Scholar
- Hung CC, Hsiao CF, Wang JL, Chen MY, Hsieh SM, Sheng WH, et al. Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study. Int J STD AIDS. 2005;16:673–6.PubMedView ArticleGoogle Scholar
- Chopra S, Arora U. Skin and mucocutaneous manifestations: Useful clinical predictors of HIV/AIDS. J Clin Diagn Res. 2012;6:1695–8.PubMedPubMed CentralGoogle Scholar
- Kore SD, Kanwar AJ, Vinay K, Wanchu A. Pattern of mucocutaneous manifestations in human immunodeficiency virus-positive patients in North India. Indian J Sex Transm Dis. 2013;34:19–24.PubMedPubMed CentralView ArticleGoogle Scholar
- Mali RJ, Wankhade AB, Ghadage DP, Muley VA, Bhore AV. Cutaneous manifestations in HIV infected patients in rural area. J Pure Appl Microbiol. 2012;6:467–70.Google Scholar
- Panda S, Sarkar S, Mandal BK, Singh TB, Singh KL, Mitra DK, et al. Epidemic of herpes zoster following HIV epidemic in Manipur, India. J Infect. 1994;28:167–73.PubMedView ArticleGoogle Scholar
- Panda S, Kamei G, Pamei M, Sarkar S, Sarkar K, Singh ND, et al. Clinical features of HIV infection in drug users of Manipur. Natl Med J India. 1994;7:267–9.PubMedGoogle Scholar
- Antwal M, Gurjar R, Chidrawar S, Pawar J, Gaikwad S, Panchal N, et al. Clinical profile of HIV infected patients attending a HIV referral clinic in Pune. India Indian J Med Res. 2014;140:271–7.PubMedGoogle Scholar
- Lloyd A. HIV infection and AIDS. P N G Med J. 1996;39:174–80.PubMedGoogle Scholar
- Satishchandra P, Nalini A, Gourie-Devi M, Khanna N, Santosh V, Ravi V, et al. Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989–96). Indian J Med Res. 2000;111:14–23.PubMedGoogle Scholar
- Srikanth KP, Vijayakumar S, Aparna, Mallikarjun. A hospital based cross sectional study of mucocutaneous manifestations in the HIV infected. Int J Collab Res Intern Med Public Health. 2010;2:50–78.Google Scholar
- Fernandes MS, Bhat RM. Spectrum of mucocutaneous manifestations in human immunodeficiency virus-infected patients and its correlation with CD4 lymphocyte count. Int J STD AIDS. 2015;26:414–9.PubMedView ArticleGoogle Scholar
- Singh HR, Singh NG, Singh TB. Estimation of CD4+ and CD8+ T-lymphocytes in human immunodeficiency virus infection and acquired immunodeficiency syndrome patients in Manipur. Indian J Med Microbiol. 2007;25:126–32.PubMedView ArticleGoogle Scholar
- Price P, Murdoch DM, Agarwal U, Lewin SR, Elliott JH, French MA. Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev. 2009;22:651–63.PubMedPubMed CentralView ArticleGoogle Scholar
- Choi WR, Seo MC, Sung KU, Lee HE, Yoon HJ. Herpes zoster immune reconstitution inflammatory syndrome in a HIV-infected patient: Case report and literature review. Infect Chemother. 2012;44:391–4.View ArticleGoogle Scholar
- Handa S, Narang T, Wanchu A. Dermatologic immune restoration syndrome: report of five cases from a tertiary care center in north India. J Cutan Med Surg. 2008;12:126–32.PubMedView ArticleGoogle Scholar
- Sharma A, Makrandi S, Modi M, Sharma A, Marfatia Y. Immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol. 2008;74:619–21.PubMedView ArticleGoogle Scholar
- Terada K, Yoshihiro K, Kawano S, Morita T. Incidence of herpes zoster in pediatricians and family practitioners Estimation of efficacy of varicella vaccine for protection against herpes zoster in the elderly. Kawasaki Med J. 1994;20:99–102.Google Scholar
- Mittal RR. Infectivity of varicella and herpes zoster. Indian J Dermatol Venereol Leprol. 1996;62:196–7.PubMedGoogle Scholar
- Chandak SO, Pandilwar PK. Epidemic of herpes zoster in a family. J Oral Maxillofacial Surg Med Pathol. 2012;24:42–4.View ArticleGoogle Scholar
- Suzuki K, Yoshikawa T, Tomitaka A, Matsunaga K, Asano Y. Detection of aerosolized varicella-zoster virus DNA in patients with localized herpes zoster. J Infect Dis. 2004;189:1009–12.PubMedView ArticleGoogle Scholar
- Suzuki K, Yoshikawa T, Tomitaka A, Suzuki K, Matsunaga K, Asano Y. Detection of varicella-zoster virus DNA in throat swabs of patients with herpes zoster and on air purifier filters. J Med Virol. 2002;66:567–70.PubMedView ArticleGoogle Scholar
- Yoshikawa T, Ihira M, Suzuki K, Suga S, Tomitaka A, Ueda H, et al. Rapid contamination of the environments with varicella-zoster virus DNA from a patient with herpes zoster. J Med Virol. 2001;63:64–6.PubMedView ArticleGoogle Scholar
- Zhai JX, Ji J, Li M. Cutaneous tuberculosis complicated with squamous cell carcinoma. J Clin Dermatol. 2010;39:713–5.Google Scholar
- Kansal HM, Goel S. Cutaneous manifestations in cases of pulmonary tuberculosis: A clinical profile. J Indian Acad Clin Med. 2013;14:284–6.Google Scholar
- Kulkarni AG, Brid NS. Images in clinical medicine. Herpes zoster. N Engl J Med. 1995;332:1684.PubMedView ArticleGoogle Scholar
- Regunath H, Shivashankara KN, Sundeep KB, Bhaskar AP. Reactivation of Herpes zoster in an adult with Plasmodium infection. J Vector Borne Dis. 2008;45:251–3.PubMedGoogle Scholar
- Park B, Yun SJ, Lee JB, Lee SC, Won YH, Kim SJ. Analysis of dermatoses in pregnant patients. Korean J Dermatol. 2013;51:249–57.Google Scholar
- Kim WJ, Kim JY, Lee WJ, Lee SJ, Kim DW, Ko HC, et al. Investigation of the clinical manifestations of herpes zoster during pregnancy and its impact on the perinatal outcome. Korean J Dermatol. 2010;48:941–7.Google Scholar
- Thami GP, Kanwar AJ. Herpes zoster during pregnancy near term: to treat or not to treat? Aust N Z J Obstet Gynaecol. 1999;39:371.PubMedView ArticleGoogle Scholar
- Tsai YG, Lai JH, Kuo SY, Chen HC, Chang DM. Thymoma and hypogammaglobulinemia (Good’s syndrome): a case report. J Microbiol Immunol Infect. 2005;38:218–20.PubMedGoogle Scholar
- Chen JY, Chang CY, Lin YS, Hu ML. Nutritional factors in herpes zoster, postherpetic neuralgia, and zoster vaccination. Popul Health Manag. 2012;15:391–7.PubMedView ArticleGoogle Scholar
- Chao CT, Lee SY, Yang WS, Yen CJ, Chiang CK, Huang JW, et al. Serum vitamin D levels are positively associated with varicella zoster immunity in chronic dialysis patients. Sci Rep. 2014;4:7371.PubMedView ArticleGoogle Scholar
- Chao CT, Lai CF, Huang JW. Risk factors for herpes zoster reactivation in maintenance hemodialysis patients. Eur J Intern Med. 2012;23:711–5.PubMedView ArticleGoogle Scholar
- Chi CY, Chu CC, Liu JP, Lin CH, Ho MW, Lo WJ, et al. Anti-IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood. 2013;121:1357–66.PubMedView ArticleGoogle Scholar
- Cho JW, Shin DH, Lee KS. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea. J Dermatol Sci. 2007;45:213–5.PubMedView ArticleGoogle Scholar
- Park SJ, Cho JW, Lee KS. Single nucleotide polymorphisms of interleukin-10 promoter gene in Korean herpes zoster patients. Korean J Dermatol. 2006;44:1325–31.Google Scholar
- Yuan LL, Wang LX, Xie YM, Yang W, Yang ZX, Zhuang Y, et al. Analysis on clinical features and treatment of herpes zoster patients hospitalized in real world. Zhongguo Zhongyao Zazhi. 2014;39:3469–73.PubMedGoogle Scholar
- Oh HM, Ho AY, Chew SK, Monteiro EH. Clinical presentation of herpes zoster in a Singapore hospital. Singapore Med J. 1997;38:471–4.PubMedGoogle Scholar
- Vikrant S. Long-term clinical outcomes of peritoneal dialysis patients: 9-year experience of a single center from north India. Perit Dial Int. 2014;34:426–33.PubMedPubMed CentralView ArticleGoogle Scholar
- Sato T, Inoue T, Endo K, Watanabe Y, Kikuta T, Tsuda M, et al. End-stage renal disease (ESRD) contributes to the increasing prevalence of herpes zoster. NDT Plus. 2009;2:263–4.PubMedPubMed CentralGoogle Scholar
- Muraya Y. Clinical and immunological evaluation of infection in patients on hemodialysis. J Infect Chemother. 1996;2:247–53.View ArticleGoogle Scholar
- Iwamoto M, Kamimura T, Nagashima T, Kamata Y, Aoki Y, Onishi S, et al. Healthcare-associated infections in rheumatology in Japan. Rheumatol Int. 2012;32:801–4.PubMedView ArticleGoogle Scholar
- Nishimaki T, Watanabe K, Satho Y, Okubo M, Kaise S, Miyata M, et al. Viral, fungal and mycobacterial infections in patients with systemic lupus erythematosus. Jpn J Rheumatol. 1999;9:45–54.Google Scholar
- Ishikawa O, Abe M, Miyachi Y. Herpes zoster in Japanese patients with systemic lupus erythematosus. Clin Exp Dermatol. 1999;24:327–8.PubMedView ArticleGoogle Scholar
- Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol. 2013;48:595–600.PubMedView ArticleGoogle Scholar
- Binitha MP, Sarita SP, Manju M. Photoletter to the editor: Squamous cell carcinoma associated with and masquerading as molluscum contagiosum. J Dermatol Case Rep. 2013;7:103–5.PubMedPubMed CentralView ArticleGoogle Scholar
- Rajagopal R, Arora PN, Ramasastry CV, Kar PK. Skin changes in internal malignancy. Indian J Dermatol Venereol Leprol. 2004;70:221–5.PubMedGoogle Scholar
- Ayyamperumal A, Tharini G, Ravindran V, Parveen B. Cutaneous manifestations of internal malignancy. Indian J Dermatol. 2012;57:260–4.PubMedPubMed CentralView ArticleGoogle Scholar
- Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis. 2009;200:1606–10.PubMedView ArticleGoogle Scholar
- Mahajan S, Koranne R, Sharma S. Cutaneous manifestation of diabetes melitus. Indian J Dermatol Venereol Leprol. 2003;69:105–8.PubMedGoogle Scholar
- Yang YW, Chen YH, Lin HW. Risk of herpes zoster among patients with psychiatric diseases: a population-based study. J Eur Acad Dermatol Venereol. 2011;25:447–53.PubMedView ArticleGoogle Scholar
- Lee JY, Yoon NH, Park SD. A clinical study of the nature of pain associated with herpes zoster. Korean J Dermatol. 2006;44:1298–303.Google Scholar
- Yang YD, Wu JJ, Bi JJ, Lu YG, Zhu TY. Retrospective study of the characteristics of postherpetic neuralgia in 178 cases. Chin J Clin Rehab. 2005;9:23–5.Google Scholar
- Herr H. Prognostic factors of postherpetic neuralgia. J Korean Med Sci. 2002;17:655–9.PubMedPubMed CentralView ArticleGoogle Scholar
- Cho SI, Lee CH, Park GH, Park CW, Kim HO. Use of S-LANSS, a tool for screening neuropathic pain, for predicting postherpetic neuralgia in patients after acute herpes zoster events: a single-center, 12-month, prospective cohort study. J Pain. 2014;15:149–56.PubMedView ArticleGoogle Scholar
- Zhu SM, Liu YM, An ED, Chen QL. Influence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgia. J Zhejiang Univ Sci B. 2009;10:625–30.PubMedPubMed CentralView ArticleGoogle Scholar
- Imafuku S, Nakayama J, Higa K, Furue M, Takahara M, Katayama I, et al. One-year follow-up of zoster-associated pain in 764 immunocompetent patients with acute herpes zoster treated with famciclovir (FAMILIAR study). J Eur Acad Dermatol Venereol. 2014;28:1716–22.PubMedView ArticleGoogle Scholar
- Kanbayashi Y, Onishi K, Fukazawa K, Okamoto K, Ueno H, Takagi T, et al. Predictive factors for postherpetic neuralgia using ordered logistic regression analysis. Clin J Pain. 2012;28:712–14.PubMedView ArticleGoogle Scholar
- Zhang DP, He L. Risk factors and prevention measures of postherpetic neuralgia. Chin J Clin Rehab. 2005;9:118–9.Google Scholar
- Nithyanandam S, Dabir S, Stephen J, Joseph M. Eruption severity and characteristics in herpes zoster ophthalmicus: correlation with visual outcome, ocular complications, and postherpetic neuralgia. Int J Dermatol. 2009;48:484–7.PubMedView ArticleGoogle Scholar
- Nahm FS, Kim SH, Kim HS, Shin JW, Yoo SH, Yoon MH, et al. Survey on the treatment of postherpetic neuralgia in Korea; multicenter study of 1,414 patients. Korean J Pain. 2013;26:21–6.PubMedPubMed CentralView ArticleGoogle Scholar
- Chen JY, Lan KM, Sheu MJ, Tseng SF, Weng SF, Hu ML. Peptic ulcer as a risk factor for postherpetic neuralgia in adult patients with herpes zoster. J Med Virol. 2015;87:222–9.PubMedView ArticleGoogle Scholar
- Sumiyama D, Kikkawa EF, Kita YF, Shinagawa H, Mabuchi T, Ozawa A, et al. HLA alleles are associated with postherpetic neuralgia but not with herpes zoster. Tokai J Exp Clin Med. 2008;33:150–3.PubMedGoogle Scholar
- Sato M, Ohashi J, Tsuchiya N, Kashiwase K, Ishikawa Y, Arita H, et al. Association of HLA-A*3303-B*4403-DRB1*1302 haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia (PHN) in the Japanese population. Genes Immun. 2002;3:477–81.PubMedView ArticleGoogle Scholar
- Ozawa A, Sasao Y, Iwashita K, Miyahara M, Sugai J, Iizuka M, et al. HLA-A33 and -B44 and susceptibility to postherpetic neuralgia (PHN). Tissue Antigens. 1999;53:263–8.PubMedView ArticleGoogle Scholar
- Sato-Takeda M, Ihn H, Ohashi J, Tsuchiya N, Satake M, Arita H, et al. The human histocompatibility leukocyte antigen (HLA) haplotype is associated with the onset of postherpetic neuralgia after herpes zoster. Pain. 2004;110:329–36.PubMedView ArticleGoogle Scholar
- Kirizume K, Imataki O, Shintani T, Fujihara S, Waki F, Ohue Y, et al. Aggravated post-herpetic neuralgia due to bortezomib. Rinsho Ketsueki. 2008;49:331–4.PubMedGoogle Scholar
- Choi WS, Kwon SS, Lee J, Choi SM, Lee JS, Eom JS, et al. Immunity and the burden of herpes zoster. J Med Virol. 2014;86:525–30.PubMedView ArticleGoogle Scholar
- Mehta J, Mahajan V, Khanna S. Disseminated zoster with polyneuritis cranialis and motor radiculopathy: Letter to editor. Neurol India. 2002;50:228–9.PubMedGoogle Scholar
- Kim SH, Suh MK. The clinical features of herpes zoster ophthalmicus in inpatients. Korean J Dermatol. 2008;46:1337–43.Google Scholar
- Ando K, Kohmoto H. Clinical features of herpes zoster ophthalmicus. Jpn J Clin Ophthalmol. 2000;54:385–7.Google Scholar
- Amaki S, Suzuki S, Shinbo R, Ando R, Oguchi Y, Shimizu H, et al. A statistical study of ocular complications of herpes zoster ophthalmicus and its prolongation factors. Nihon Ganka Gakkai Zasshi. 1995;99:289–95.PubMedGoogle Scholar
- Yoshida M, Hayasaka S, Yamada T, Yanagisawa S, Hayasaka Y, Nakamura N, et al. Ocular findings in Japanese patients with varicella-zoster virus infection. Ophthalmologica. 2005;219:272–5.PubMedView ArticleGoogle Scholar
- Kimata N, Nakagawa H, Araki H. Clinical features of herpes zoster keratitis. Jpn J Clin Ophthalmol. 1996;50:1113–6.Google Scholar
- Matsuda A, Tagawa Y, Abe N, Tsuda K, Matsuda H. Classification of corneal complications from varicella zoster virus. Jpn J Clin Ophthalmol. 1995;49:1519–23.Google Scholar
- McDonald EM, Patel DV, McGhee CN. A prospective study of the clinical characteristics of patients with herpes simplex and varicella zoster keratitis, presenting to a New Zealand emergency eye clinic. Cornea. 2015;34:279–84.PubMedView ArticleGoogle Scholar
- Zheng Y, Shi J. Clinical analysis of 58 cases of herpetic keratouveitis. Chin Ophthalmic Res. 2009;27:809–11.Google Scholar
- Thean JH, Hall AJ, Stawell RJ. Uveitis in Herpes zoster ophthalmicus. Clin Experiment Ophthalmol. 2001;29:406–10.PubMedView ArticleGoogle Scholar
- Hanajiri M, Matsumoto T, Hatano H, Ohno S. Herpes zoster ophthalmicus without skin eruptions. Jpn J Clin Ophthalmol. 1994;48:658–60.Google Scholar
- Kwok SK, Ho PCP, Chau GKO. Herpes zoster ophthalmicus - A family physician’s perspective. Hong Kong Pract. 2001;23:57–62.Google Scholar
- Albietz JM, Lenton LM. Late reactivation of herpes zoster keratitis results in band keratopathy. Optom Vis Sci. 2014;91:e149–55.PubMedView ArticleGoogle Scholar
- Cao L. Ophthalmic symptoms in AIDS. Int J Ophthalmol. 2009;9:393–4.Google Scholar
- Nithyanandam S, Joseph M, Stephen J. Ocular complications and loss of vision due to herpes zoster ophthalmicus in patients with HIV infection and a comparison with HIV-negative patients. Int J STD AIDS. 2013;24:106–9.PubMedView ArticleGoogle Scholar
- Gupta N, Sachdev R, Sinha R, Titiyal JS, Tandon R. Herpes zoster ophthalmicus: disease spectrum in young adults. Middle East Afr J Ophthalmol. 2011;18:178–82.PubMedPubMed CentralView ArticleGoogle Scholar
- Babu K, Kini R, Philips M, Subbakrishna DK. Clinical profile of isolated viral anterior uveitis in a South Indian patient population. Ocul Immunol Inflamm. 2014;22:356–9.PubMedView ArticleGoogle Scholar
- Ichikawa T, Sakai J, Yamauchi Y, Minoda H, Usui M. A study of 44 patients with Kirisawa type uveitis. Nihon Ganka Gakkai Zasshi. 1997;101:243–7.PubMedGoogle Scholar
- Tan WJ, Poh EW, Wong PY, Ho SL, Lim WK, Teoh SC. Trends in patterns of anterior uveitis in a tertiary institution in Singapore. Ocul Immunol Inflamm. 2013;21:270–5.PubMedView ArticleGoogle Scholar
- Wang TJ, Hu CC, Lin HC. Increased risk of anterior uveitis following herpes zoster: a nationwide population-based study. Arch Ophthalmol. 2012;130:451–5.PubMedView ArticleGoogle Scholar
- Sims JL, Yeoh J, Stawell RJ. Acute retinal necrosis: A case series with clinical features and treatment outcomes. Clin Exp Ophthalmol. 2009;37:473–7.PubMedView ArticleGoogle Scholar
- Roy R, Pal BP, Mathur G, Rao C, Das D, Biswas J. Acute retinal necrosis: clinical features, management and outcomes–a 10 year consecutive case series. Ocul Immunol Inflamm. 2014;22:170–4.PubMedView ArticleGoogle Scholar
- Sodeyama H, Todokoro D, Yamada N, Kishi S. Identification of causative virus and clinical course of acute retinal necrosis. Jpn J Clin Ophthalmol. 2014;68:947–52.Google Scholar
- Itoh N, Matsumura N, Ogi A, Nishide T, Imai Y, Kanai H, et al. High prevalence of herpes simplex virus type 2 in acute retinal necrosis syndrome associated with herpes simplex virus in Japan. Am J Ophthalmol. 2000;129:404–5.PubMedView ArticleGoogle Scholar
- Grover R, Ratho RK, Gupta V, Mahajan RC, Gupta A. Role of viral serology in the diagnosis of acute retinal necrosis syndrome. Ind J Pathol Microbiol. 2002;45:269–71.Google Scholar
- Madhavan HN. Laboratory investigations on viral and Chlamydia trachomatis infections of the eye: Sankara Nethralaya experiences. Indian J Ophthalmol. 1999;47:241–6.PubMedGoogle Scholar
- Mizuuchi K, Namba K, Kotake S, Ohno S. Clinical features of acute retinal necrosis at Hokkaido University Hospital. Nihon Ganka Gakkai Zasshi. 2008;112:136–40.PubMedGoogle Scholar
- Shimakawa M, Sato N. A case of AIDS complicated by progressive outer retinal necrosis. Nihon Ganka Gakkai Zasshi. 1999;103:137–43.PubMedGoogle Scholar
- Sittivarakul W, Aui-aree N. Clinical features, management and outcomes of progressive outer retinal necrosis (PORN) in southern Thailand. J Med Assoc Thai. 2009;92:360–6.PubMedGoogle Scholar
- Oshitari K, Arimoto H, Suzuki S, Oguchi Y. Rapidly progressive outer retinal necrosis in a patient with acquired immunodeficiency syndrome. Nihon Ganka Gakkai Zasshi. 1994;98:1141–6.PubMedGoogle Scholar
- Gill H, Cheung J, Wong I, Lie AK, Kwong YL. Varicella zoster virus progressive outer retinal necrosis after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2012;157:279.PubMedView ArticleGoogle Scholar
- Kim SJ, Park SJ, Yu HG, Kim NJ, Jang HC, Oh MD. Ocular manifestations of acquired immunodeficiency syndrome in Korea. J Korean Med Sci. 2012;27:542–6.PubMedPubMed CentralView ArticleGoogle Scholar
- Lim WK, Chee SP, Nussenblatt RB. Progression of varicella-zoster virus necrotizing retinopathy in an HIV-negative patient with transient immune deviation. Graefes Arch Clin Exp Ophthalmol. 2005;243:607–9.PubMedView ArticleGoogle Scholar
- Tseng CC, Chen SN, Hwang JF, Lin CJ, Chen HS. Progressive outer retinal necrosis associated with occlusive vasculitis in acquired immunodeficiency syndrome. J Formos Med Assoc. 2015;114:469–72.PubMedView ArticleGoogle Scholar
- Inoue Y, Takano M, Kawai H, Ichibe Y, Shimizu K. Progressive outer retinal necrosis in a patient with interstitial nephritis. Jpn J Clin Ophthalmol. 2006;60:1087–90.Google Scholar
- Miyaoka Y, Suzuki J, Yamauchi Y, Goto H. A bilateral case of progressive outer retinal necrosis with retinal detachment resistant to antiviral treatments. Jpn J Clin Ophthalmol. 2008;62:489–92.Google Scholar
- Ozaki H, Jane H, Inoue H, Kozawa M, Kondo H, Uchio E. Outcome of treatment for acute retinal necrosis. Jpn J Clin Ophthalmol. 2011;65:1819–25.Google Scholar
- Hong J. Discuss on the diagnosis and treatment of viral cornea endotheliitis. Ophthalmol China. 2010;19:158–60.Google Scholar
- Wang AG, Liu JH, Hsu WM, Lee AF, Yen MY. Optic neuritis in herpes zoster ophthalmicus. Jpn J Ophthalmol. 2000;44:550–4.PubMedView ArticleGoogle Scholar
- Menon V, Kumar G, Tandon R. Optic neuropathy secondary to herpes zoster ophthalmicus. Indian J Ophthalmol. 1995;43:78–9.PubMedGoogle Scholar
- Suraiya MS, Norazlina B, Carmen C, Muhaya M. Bilateral optic neuritis in pregnancy. Med J Malaysia. 2003;58:771–3.PubMedGoogle Scholar
- Obata H, Yamagami S, Saito S, Sakai O, Tsuru T. A case of acute dacryoadenitis associated with herpes zoster ophthalmicus. Jpn J Ophthalmol. 2003;47:107–9.PubMedView ArticleGoogle Scholar
- Yokoyama C, Mori S, Kamada A, Kase S, Ishida S. A case of herpes zoster ophthalmicus with acute dacryoadenitis as the initial manifestation. Jpn J Clin Ophthalmol. 2011;65:945–8.Google Scholar
- Yong VK, Yip CC, Yong VS. Herpes zoster ophthalmicus and the superior orbital fissure syndrome. Singapore Med J. 2001;42:485–6.PubMedGoogle Scholar
- Bourke RD, Pyle J. Herpes zoster ophthalmicus and the orbital apex syndrome. Aust New Zealand J Ophthalmol. 1994;22:77–80.View ArticleGoogle Scholar
- Saxena R, Phuljhele S, Aalok L, Sinha A, Menon V, Sharma P, et al. A rare case of orbital apex syndrome with herpes zoster ophthalmicus in a human immunodeficiency virus-positive patient. Indian J Ophthalmol. 2010;58:527–30.PubMedPubMed CentralView ArticleGoogle Scholar
- Biswas J, Deka S, Padmaja S, Madhavan HN, Kumarasamy N, Solomon S. Central retinal vein occlusion due to herpes zoster as the initial presenting sign in a patient with acquired immunodeficiency syndrome (AIDS). Ocul Immunol Inflamm. 2001;9:125–30.PubMedView Article